Bis-modified bicyclic nucleic acid analogs

ABSTRACT

The present disclosure describes bis-modified bicyclic nucleosides and oligomeric compounds that can be prepared comprising at least one of these bis-modified bicyclic nucleosides. More particularly, the bis-modified bicyclic nucleosides have at least one substituent group at the 5′-methylene and on the bridge methylene and can be chiral. These bis-modified bicyclic nucleosides are expected to be useful for enhancing one or more property of oligomeric compounds including for example enhancing nuclease resistance.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present Application is a continuation of U.S. application Ser. No.12/331,226, filed Dec. 9, 2008; which is continuation in part of U.S.application Ser. No. 11/747,057, filed May 10, 2007, now issued as U.S.Pat. No. 7,547,684; which claims benefit to U.S. Provisional ApplicationSer. No. 60/747,059, filed May 11, 2006, each of which are incorporatedherein by reference in their entirety.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format. The Sequence Listing is provided as a file entitledCHEM0029USC2SEQ.TXT, created on Jan. 13, 2010 which is 8 Kb in size. Theinformation in the electronic format of the sequence listing isincorporated herein by reference in its entirety.

FIELD OF THE INVENTION

Provided herein are novel bis-modified bicyclic nucleosides andoligomeric compounds prepared therefrom. More particularly, the bismodified bicyclic nucleosides each have at least one non H substituentgroup “Q” located on the bridge (2′-O—C(Q₁)(Q₂)-4′) and at least onefurther non H substituent group “Z” located on the 5′-methylene group[5′-C(Z₂)(Z₂)]. The bis-substituted bicyclic nucleosides are expected tobe useful for enhancing one or more properties of the oligomericcompounds they are incorporated into such as for example nucleaseresistance.

BACKGROUND OF THE INVENTION

Antisense technology is an effective means for reducing the expressionof one or more specific gene products and can therefore prove to beuniquely useful in a number of therapeutic, diagnostic, and researchapplications. Chemically modified nucleosides are routinely used forincorporation into antisense sequences to enhance one or more propertiessuch as for example nuclease resistance. One such group of chemicalmodifications includes bicyclic nucleosides wherein the furanose portionof the nucleoside includes a bridge connecting two atoms on the furanosering thereby forming a bicyclic ring system. Such bicyclic nucleosideshave various names including BNA's and LNA's for bicyclic nucleic acidsor locked nucleic acids respectively.

Various BNA's have been prepared and reported in the patent literatureas well as in scientific literature, see for example: Singh et al.,Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54,3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A., 2000, 97,5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222;Wengel et al., PCT International Application number PCT/DK98/00303(published as WO 99/14226 on Mar. 25, 1999), filed Sep. 14, 1998; Singhet al., J. Org. Chem., 1998, 63, 10035-10039, the text of each isincorporated by reference herein, in their entirety. Examples of issuedUS patents and published applications include for example: U.S. Pat.Nos. 6,770,748, 6,268,490 and 6,794,499 and published U.S. applications20040219565, 20040014959, 20030207841, 20040192918, 20030224377,20040143114, 20030087230 and 20030082807, the text of each isincorporated by reference herein, in their entirety.

Various 5′-modified nucleosides have been prepared and reported in thepatent literature as well as in scientific literature, see for example:Mikhailov et al., Nucleosides and Nucleotides, 1991, 10, 393-343; Sahaet al., J. Org. Chem., 1995, 60, 788-789; Beigleman et al., Nucleosidesand Nucleotides, 1995, 14, 901-905; Wang, et al., Bioorganic & MedicinalChemistry Letters, 1999, 9, 885-890; and PCT International ApplicationWO94/22890 published Oct. 13, 1994, the text of each is incorporated byreference herein, in their entirety.

Bicyclic nucleosides having a single substituent group on the bridgee.g. a 6-substituent group (4′-CH(R)—O-2′) and oligomeric compoundsincorporating these nucleosides have been reported in a commonly ownedissued U.S. Pat. No. 7,339,845, issued Jul. 15, 2008, the text of whichis incorporated by reference herein, in its entirety. Bicyclicnucleosides having two substituent groups on the bridge(4′-C(R₁)(R₂)—O-2′) and oligomeric compounds incorporating thesenucleosides have been reported in commonly owned published InternationalApplication, WO 2007/090071 Published Aug. 9, 2007, the text of which isincorporated by reference herein, in its entirety.

Consequently, there remains an ongoing need for agents that specificallyregulate gene expression via antisense mechanisms. Disclosed herein arebis-modified bicyclic nucleosides and antisense compounds preparedtherefrom that are expected to be useful for modulating gene expressionpathways, including those relying on mechanisms of action such asRNaseH, RNAi and dsRNA enzymes, as well as other antisense mechanismsbased on target degradation or target occupancy. One having skill in theart, once armed with this disclosure will be able, without undueexperimentation, to identify, prepare and exploit antisense compoundsfor these uses.

BRIEF SUMMARY OF THE INVENTION

Provided herein are novel bis-modified bicyclic nucleosides andoligomeric compounds prepared therefrom. More particularly, the bismodified bicyclic nucleosides each have at least one non H substituentgroup “Q” located on the bridge (2′-O—C(Q₁)(Q₂)-4′) and at least onefurther non H substituent group “Z” located on the 5′-methylene group[5′-C(Z₂)(Z₂)]. The bis-substituted bicyclic nucleosides are expected tobe useful for enhancing one or more properties of the oligomericcompounds they are incorporated into such as for example nucleaseresistance. In certain embodiments, the oligomeric compounds andcompositions provided herein that incorporate one or more of thebis-substituted bicyclic nucleosides are expected to hybridize to aportion of a target RNA resulting in loss of normal function of thetarget RNA.

The variables are defined individually in further detail herein. It isto be understood that the bis-substituted bicyclic nucleosides providedherein and the oligomeric compounds comprising at least one of thesebis-substituted bicyclic nucleosides include all combinations of theembodiments disclosed and variables defined herein.

In certain embodiments, bicyclic nucleosides are provided herein havingFormula I:

wherein:

Bx is a heterocyclic base moiety;

one of T₁ and T₂ is H or a hydroxyl protecting group and the other of T₁and T₂ is H, a hydroxyl protecting group or a reactive phosphorus group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, Z₁ and Z₂ are each, independently, C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl or substituted C₂-C₆ alkynyl. In certain embodiments, Z₁ and Z₂are each CH₃. In certain embodiments, one of Z₁ and Z₂ is H. In certainembodiments, one of Z₁ and Z₂ is H and the other one of Z₁ and Z₂ issubstituted C₁-C₆ alkyl. In certain embodiments, one of Z₁ and Z₂ is Hand the other one of Z₁ and Z₂ is CH₂F, CHF₂ or CF₃. In certainembodiments, one of Z₁ and Z₂ is H and the other one of Z₁ and Z₂ isC₁-C₆ alkyl. In certain embodiments, one of Z₁ and Z₂ is H and the otherone of Z₁ and Z₂ is CH₃.

In certain embodiments, Q₁ and Q₂ are each, independently, C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl, substituted C₂-C₆ alkynyl, thiol or substituted thiol. Incertain embodiments, Q₁ and Q₂ are each CH₃. In certain embodiments, oneof Q₁ and Q₂ is H. In certain embodiments, one of Q₁ and Q₂ is H and theother one of Q₁ and Q₂ is substituted C₁-C₆ alkyl. In certainembodiments, one of Q₁ and Q₂ is H and one of Q₁ and Q₂ is CH₂F, CHF₂ orCF₃. In certain embodiments, one of Q₁ and Q₂ is H and the other one ofQ₁ and Q₂ is C₁-C₆ alkyl. In certain embodiments, one of Q₁ and Q₂ is Hand the other one of Q₁ and Q₂ is CH₃.

In certain embodiments, Q₁ and Q₂ together are methylene (═CH₂). Incertain embodiments, Q₁ and Q₂ together are methylene (═CH₂), one of Z₁and Z₂ is CH₃ and the other one of Z₁ and Z₂ is H.

In certain embodiments, bicyclic nucleosides are provided herein havingFormula II:

wherein:

Bx is a heterocyclic base moiety;

one of T₁ and T₂ is H or a hydroxyl protecting group and the other of T₁and T₂ is H, a hydroxyl protecting group or a reactive phosphorus group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, bicyclic nucleosides are provided having FormulaII wherein Z₂ and Q₂ are each H. In certain embodiments, bicyclicnucleosides are provided having Formula II wherein Z₂ and Q₂ are each Hand Z₁ and Q₁ are each CH₃.

In certain embodiments, bicyclic nucleosides are provided having FormulaII wherein Z₂ and Q₁ are each H. In certain embodiments, bicyclicnucleosides are provided having Formula II wherein Z₂ and Q₁ are each Hand Z₁ and Q₂ are each CH₃.

In certain embodiments, bicyclic nucleosides are provided having FormulaII wherein Z₁ and Q₂ are each H. In certain embodiments, bicyclicnucleosides are provided having Formula II wherein Z₁ and Q₂ are each Hand Z₂ and Q₁ are each CH₃.

In certain embodiments, bicyclic nucleosides are provided having FormulaII wherein Z₁ and Q₁ are each H. In certain embodiments, bicyclicnucleosides are provided having Formula II wherein Z₁ and Q₁ are each Hand Z₂ and Q₂ are each CH₃.

In certain embodiments, Bx is uracil, 5-thiazolo-uracil, 2-thio-uracil,5-propynyl-uracil, thymine, 2′-thio-thymine, cytosine, 5-methylcytosine,5-thiazolo-cytosine, 5-propynyl-cytosine, adenine, guanine,2,6-diaminopurine, 1H-pyrimido[5,4-b][1,4-benzoxazin-2(3H)-one),1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one,9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one,2H-pyrimido[4,5-b]indol-2-one orH-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one. In certainembodiments, Bx is uracil, thymine, cytosine, 5-methylcytosine,2,6-diaminopurine, adenine or guanine.

In certain embodiments, T₁ is selected from acetyl, benzyl,t-butyldimethylsilyl, t-butyl-diphenylsilyl and dimethoxytrityl. Incertain embodiments, T₁ is 4,4′-dimethoxytrityl. In certain embodiments,T₂ is a reactive phosphorus group. In certain embodiments, T₂ is areactive phosphorus group selected from diisopropylcyanoethoxyphosphoramidite or H-phosphonate. In certain embodiments, T₁ is4,4′-dimethoxytrityl and T₂ is diisopropylcyanoethoxy phosphoramidite.

In certain embodiments, oligomeric compounds are provided herein havingat least one bicyclic nucleoside of Formula III:

wherein independently for each bicyclic nucleoside having Formula III:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking grouplinking the bicyclic nucleoside of Formula III to the oligomericcompound or one of T₃ and T₄ is an internucleoside linking group linkingthe bicyclic nucleoside of Formula III to the oligomeric compound andthe other of T₃ and T₄ is H, a hydroxyl protecting group, a linkedconjugate group or a 5′ or 3′-terminal group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, Z₁ and Z₂ are each, independently, C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl or substituted C₂-C₆ alkynyl for essentially each bicyclicnucleoside having Formula III. In certain embodiments, Z₁ and Z₂ areeach CH₃ for essentially each bicyclic nucleoside having Formula III.

In certain embodiments, one of Z₁ and Z₂ is H for essentially eachbicyclic nucleoside having Formula III. In certain embodiments, one ofZ₁ and Z₂ is H and the other one of Z₁ and Z₂ is substituted C₁-C₆ alkylfor essentially each bicyclic nucleoside having Formula III. In certainembodiments, one of Z₁ and Z₂ is H and the other one of Z₁ and Z₂ isCH₂F, CHF₂ or CF₃ for essentially each bicyclic nucleoside havingFormula III. In certain embodiments, one of Z₁ and Z₂ is H and the otherone of Z₁ and Z₂ is C₁-C₆ alkyl for essentially each bicyclic nucleosidehaving Formula III. In certain embodiments, one of Z₁ and Z₂ is H andthe other one of Z₁ and Z₂ is CH₃ for essentially each bicyclicnucleoside having Formula III.

In certain embodiments, Q₁ and Q₂ are each, independently, C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl, substituted C₂-C₆ alkynyl, thiol or substituted thiol foressentially each bicyclic nucleoside having Formula III. In certainembodiments, Q₁ and Q₂ are each CH₃ for essentially each bicyclicnucleoside having Formula III.

In certain embodiments, one of Q₁ and Q₂ is H for essentially eachbicyclic nucleoside having Formula III. In certain embodiments, one ofQ₁ and Q₂ is H and the other one of Q₁ and Q₂ is substituted C₁-C₆ alkylfor essentially each bicyclic nucleoside having Formula III. In certainembodiments, one of Q₁ and Q₂ is H and other one of Q₁ and Q₂ is CH₂F,CHF₂ or CF₃ for essentially each bicyclic nucleoside having Formula III.In certain embodiments, one of Q₁ and Q₂ is H and the other one of Q₁and Q₂ is C₁-C₆ alkyl for essentially each bicyclic nucleoside havingFormula III. In certain embodiments, one of Q₁ and Q₂ is H and the otherone of Q₁ and Q₂ is CH₃ for essentially each bicyclic nucleoside havingFormula III.

In certain embodiments, Q₁ and Q₂ together are methylene (═CH₂) foressentially each bicyclic nucleoside having Formula III. In certainembodiments, Q. and Q₂ together are methylene (═CH₂), one of Z₁ and Z₂is CH₃ and the other one of Z₁ and Z₂ is H for essentially each bicyclicnucleoside having Formula III.

In certain embodiments, oligomeric compounds are provided herein havingat least one bicyclic nucleoside of Formula IV:

wherein independently for each bicyclic nucleoside having Formula IV:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking grouplinking the bicyclic nucleoside of Formula IV to the oligomeric compoundor one of T₃ and T₄ is an internucleoside linking group linking thebicyclic nucleoside of Formula IV to the oligomeric compound and theother of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugategroup or a 5′ or 3′-terminal group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₂ and Q₂ areeach H for essentially each bicyclic nucleoside having Formula IV. Incertain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₂ and Q₂ areeach H and Z₁ and Q₁ are each CH₃ for essentially each bicyclicnucleoside having Formula IV.

In certain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₂ and Q₁ areeach H for essentially each bicyclic nucleoside having Formula IV. Incertain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₂ and Q₁ areeach H and Z₁ and Q₂ are each CH₃ for essentially each bicyclicnucleoside having Formula IV.

In certain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₁ and Q₂ areeach H for essentially each bicyclic nucleoside having Formula IV. Incertain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₁ and Q₂ areeach H and Z₁ and Q₁ are each CH₃ for essentially each bicyclicnucleoside having Formula IV.

In certain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₁ and Q₁ areeach H for essentially each bicyclic nucleoside having Formula IV. Incertain embodiments, oligomeric compounds are provided comprising atleast one bicyclic nucleoside having Formula IV wherein Z₁ and Q₁ areeach H and Z₂ and Q₂ are each CH₃ for essentially each bicyclicnucleoside having Formula IV.

In certain embodiments, Bx is uracil, 5-thiazolo-uracil, 2-thio-uracil,5-propynyl-uracil, thymine, 2′-thio-thymine, cytosine, 5-methylcytosine,5-thiazolo-cytosine, 5-propynyl-cytosine, adenine, guanine,2,6-diaminopurine, 1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one),1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one,9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one,2H-pyrimido[4,5-b]indol-2-one orH-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one for essentially eachbicyclic nucleoside having Formula IV. Bx is uracil, thymine, cytosine,5-methylcytosine, 2,6-diaminopurine, adenine or guanine for essentiallyeach bicyclic nucleoside having Formula IV.

In certain embodiments, oligomeric compounds are provided wherein eachinternucleoside linking group is, independently, a phosphodiester orphosphorothioate. In certain embodiments, oligomeric compounds areprovided wherein each internucleoside linking group is aphosphorothioate.

In certain embodiments, oligomeric compounds are provided comprising atleast two regions wherein each region independently comprises at leasttwo contiguous bicyclic nucleosides having Formula III and wherein thetwo regions are separated by a plurality of monomeric subunits. Incertain embodiments the plurality of monomeric subunits comprise aplurality of β-D-2′-deoxyribofuranosyl nucleosides. In certainembodiments, the monomeric subunits comprise onlyβ-D-2′-deoxyribofuranosyl nucleosides.

In certain embodiments, oligomeric compounds are provided comprisingfrom about 8 to about 40 monomeric subunits. In certain embodiments,oligomeric compounds are provided comprising from about 8 to about 20monomeric subunits. In certain embodiments, oligomeric compounds areprovided comprising from about 10 to about 16 monomeric subunits. Incertain embodiments, oligomeric compounds are provided comprising fromabout 10 to about 14 monomeric subunits.

DETAILED DESCRIPTION OF THE INVENTION

Provided herein are novel bis-modified bicyclic nucleosides andoligomeric compounds prepared therefrom. More particularly, the bismodified bicyclic nucleosides each have at least one non H substituentgroup “Q” located on the bridge (2′-O—C(Q₁)(Q₂)-4′) and at least onefurther non H substituent group “Z” located on the 5′-methylene group[5′-C(Z₂)(Z₂)]. The bis-substituted bicyclic nucleosides are expected tobe useful for enhancing one or more properties of the oligomericcompounds they are incorporated into such as for example nucleaseresistance. In certain embodiments, the oligomeric compounds andcompositions provided herein that incorporate one or more of thebis-substituted bicyclic nucleosides are expected to hybridize to aportion of a target RNA resulting in loss of normal function of thetarget RNA. The oligomeric compounds are also expected to be useful asprimers and probes in diagnostic applications.

In certain embodiments, bicyclic nucleosides are provided having FormulaI:

wherein:

Bx is a heterocyclic base moiety;

one of T₁ and T₂ is H or a hydroxyl protecting group and the other of T₁and T₂ is H, a hydroxyl protecting group or a reactive phosphorus group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, bicyclic nucleosides are provided having FormulaII:

wherein:

Bx is a heterocyclic base moiety;

one of T₁ and T₂ is H or a hydroxyl protecting group and the other of T₁and T₂ is H, a hydroxyl protecting group or a reactive phosphorus group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, one of Z₁ and Z₂ is H and one of Q₁ and Q₂ is Hwherein the substituent groups that are not H (one of Z₁ and Z₂ and oneof Q₁ and Q₂) each, independently, have a particular configurationthereby providing either (R) or (S) chirality. Such chirality is adesign choice that can be determined during synthesis (see Examples 20and 21).

In certain embodiments, oligomeric compounds are provided herein havingat least one bicyclic nucleoside of Formula III:

wherein independently for each bicyclic nucleoside having Formula III:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking grouplinking the bicyclic nucleoside of Formula III to the oligomericcompound or one of T₃ and T₄ is an internucleoside linking group linkingthe bicyclic nucleoside of Formula III to the oligomeric compound andthe other of T₃ and T₄ is H, a hydroxyl protecting group, a linkedconjugate group or a 5′ or 3′-terminal group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, oligomeric compounds are provided herein havingFormula IV:

wherein independently for each bicyclic nucleoside having Formula IV:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking grouplinking the bicyclic nucleoside of Formula IV to the oligomeric compoundor one of T₃ and T₄ is an internucleoside linking group linking thebicyclic nucleoside of Formula IV to the oligomeric compound and theother of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugategroup or a 5′ or 3′-terminal group;

one of Z₁ and Z₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆alkynyl and the other one of Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl orsubstituted C₂-C₆ alkynyl;

one of Q₁ and Q₂ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆alkynyl, thiol or substituted thiol and the other one of Q₁ and Q₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol or substitutedthiol;

or Q₁ and Q₂ together are methylene (═CH₂);

each substituted group is mono or poly substituted with substituentgroups independently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁,CN, O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂;and

each J₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group.

In certain embodiments, the bis-modified bicyclic nucleosides providedherein are useful for modifying otherwise unmodified oligomericcompounds at one or more positions. Such modified oligomeric compoundscan be described as having a particular motif. Motifs amenable theoligomeric compounds incorporating at least one of the bis-modifiedbicyclic nucleosides provided herein include but are not limited to agapped motif, a hemimer motif, a blockmer motif, a fully modified motif,a positionally modified motif and an alternating motif. In conjunctionwith these motifs a wide variety of linkages can also be used includingbut not limited to phosphodiester and phosphorothioate linkages useduniformly or in combinations. The positioning of 6-modified bicyclicnucleosides and the use of linkage strategies can be easily optimizedfor the best activity for a particular target.

Representative U.S. patents that teach the preparation of representativemotifs include, but are not limited to, U.S. Pat. Nos. 5,013,830;5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133;5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain ofwhich are commonly owned with the instant application, and each of whichis herein incorporated by reference in its entirety. Motifs are alsodisclosed in International Applications PCT/US2005/019219, filed Jun. 2,2005 and published as WO 2005/121371 on Dec. 22, 2005 andPCT/US2005/019220, filed Jun. 2, 2005 and published as WO 2005/121372 onDec. 22, 2005; each of which is incorporated by reference herein in itsentirety.

The terms “stable compound” and “stable structure” are meant to indicatea Compound that is sufficiently robust to survive isolation to a usefuldegree of purity from a reaction mixture, and formulation into anefficacious therapeutic agent. Only stable Compounds are contemplatedherein.

Selected substituent groups within the compounds described herein arepresent to a recursive degree. In this context, “recursive substituent”means that a substituent may recite another instance of itself. Becauseof the recursive nature of such substituents, theoretically, a largenumber may be present in any given claim. One of ordinary skill in theart of medicinal chemistry and organic chemistry understands that thetotal number of such substituents is reasonably limited by the desiredproperties of the Compound intended. Such properties include, by way ofexample and not limitation, physical properties such as molecularweight, solubility or log P, application properties such as activityagainst the intended target, and practical properties such as ease ofsynthesis.

Recursive substituents are an intended aspect of the invention. One ofordinary skill in the art of medicinal and organic chemistry understandsthe versatility of such substituents. To the degree that recursivesubstituents are present in a claim of the invention, the total numberwill be determined as set forth above.

The terms “substituent” and “substituent group,” as used herein, aremeant to include groups that are typically added to other groups orparent compounds to enhance desired properties or give desired effects.Substituent groups can be protected or unprotected and can be added toone available site or to many available sites in a parent compound.Substituent groups may also be further substituted with othersubstituent groups and may be attached directly or via a linking groupsuch as an alkyl or hydrocarbyl group to a parent compound. Such groupsinclude without limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl,acyl (—C(O)R_(aa)), carboxyl (—C(O)O—R_(aa)), aliphatic groups,alicyclic groups, alkoxy, substituted oxo (—O—R_(aa)), aryl, aralkyl,heterocyclic, heteroaryl, heteroarylalkyl, amino (—NR_(bb)R_(cc)),imino(═NR_(bb)), amido (—C(O)NR_(bb)R_(cc) or —N(R_(bb))C(O)R_(aa)),azido (—N₃), nitro (—NO₂), cyano (—CN), carbamido (—OC(O)NR_(bb)R_(cc)or —N(R_(bb))C(O)OR_(aa)), ureido (—N(R_(bb))C(O)NR_(bb)R_(cc)),thioureido (—N(R_(bb))C(S)NR_(bb)R_(cc)), guanidinyl(—N(R_(bb))C(═NR_(bb))NR_(bb)R_(cc)), amidinyl(—C(═NR_(bb))NR_(bb)R_(cc) or —N(R_(bb))C(NR_(bb))R_(aa)), thiol(—SR_(bb)), sulfinyl (—S(O)R_(bb)), sulfonyl (—S(O)₂R_(bb)),sulfonamidyl (—S(O)₂NR_(bb)R_(cc) or —N(R_(bb))S(O)₂R_(bb)) andconjugate groups. Wherein each R_(aa), R_(bb) and R_(cc) is H, anoptionally linked chemical functional group or a further substituentgroup with a preferred list including without limitation H, alkyl,alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl,alicyclic, heterocyclic and heteroarylalkyl.

In certain embodiments, linking groups or bifunctional linking moietiessuch as those known in the art may be useful in the bis-modifiedbicyclic nucleosides or oligomeric compounds provided herein. Linkinggroups are useful for attachment of chemical functional groups,conjugate groups, reporter groups and other groups to selective sites ina parent compound. In general a bifunctional linking moiety comprises ahydrocarbyl moiety having two functional groups. One of the functionalgroups is selected to bind to a parent molecule or compound of interestand the other is selected to bind essentially any selected group such aschemical functional group or a conjugate group. In some embodiments, thelinker comprises a chain structure or an oligomer of repeating unitssuch as ethylene glycol or amino acid units. Examples of functionalgroups that are routinely used in a bifunctional linking moiety include,but are not limited to, electrophiles for reacting with nucleophilicgroups and nucleophiles for reacting with electrophilic groups. In someembodiments, bifunctional linking moieties include amino, hydroxyl,carboxylic acid, thiol, unsaturations (e.g., double or triple bonds),and the like. Some nonlimiting examples of bifunctional linking moietiesinclude 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) and6-aminohexanoic acid (AHEX or AHA). Other linking groups include, butare not limited to, substituted C₁-C₁₀ alkyl, substituted orunsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀alkynyl, wherein a nonlimiting list of preferred substituent groupsincludes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol,thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

In certain embodiments, oligomeric compounds are modified by covalentattachment of one or more 5′ or 3′-terminal groups. The term “terminalgroup” as used herein is meant to include useful groups known to the artskilled that can be placed on one or both of the 3′ and 5′-ends of anoligomeric compound for various purposes such as enabling the trackingof the oligomeric compound (a fluorescent label or other reportergroup), improving the pharmacokinetics or pharmacodynamics of theoligomeric compound (a group for enhancing uptake and delivery) orenhancing one or more other desirable properties of the oligomericcompound (group for improving nuclease stability or binding affinity).In certain embodiments, 3′ and 5′-terminal groups include withoutlimitation, one or more modified or unmodified nucleosides, conjugategroups, capping groups, phosphate moieties and protecting groups.

The term “hydrocarbyl” includes groups comprising C, O and H. Includedare straight, branched and cyclic groups having any degree ofsaturation. Such hydrocarbyl groups can include one or more heteroatomsselected from N, O and S and can be further mono or poly substitutedwith one or more substituent groups.

The term “alkyl,” as used herein, refers to a saturated straight orbranched hydrocarbon radical containing up to twenty four carbon atoms.Examples of alkyl groups include, but are not limited to, methyl, ethyl,propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like.Alkyl groups typically include from 1 to about 24 carbon atoms, moretypically from 1 to about 12 carbon atoms (C₁-C₁₂ alkyl) with from 1 toabout 6 carbon atoms being more preferred. The term “lower alkyl” asused herein includes from 1 to about 6 carbon atoms. Alkyl groups asused herein may optionally include one or more further substitutentgroups.

The term “alkenyl,” as used herein, refers to a straight or branchedhydrocarbon chain radical containing up to twenty four carbon atoms andhaving at least one carbon-carbon double bond. Examples of alkenylgroups include, but are not limited to, ethenyl, propenyl, butenyl,1-methyl-2-buten-1-yl, dienes such as 1,3-butadiene and the like.Alkenyl groups typically include from 2 to about 24 carbon atoms, moretypically from 2 to about 12 carbon atoms with from 2 to about 6 carbonatoms being more preferred. Alkenyl groups as used herein may optionallyinclude one or more further substitutent groups.

The term “alkynyl,” as used herein, refers to a straight or branchedhydrocarbon radical containing up to twenty four carbon atoms and havingat least one carbon-carbon triple bond. Examples of alkynyl groupsinclude, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, and thelike. Alkynyl groups typically include from 2 to about 24 carbon atoms,more typically from 2 to about 12 carbon atoms with from 2 to about 6carbon atoms being more preferred. Alkynyl groups as used herein mayoptionally include one or more further substitutent groups.

The term “aminoalkyl” as used herein, refers to an amino substitutedalkyl radical. This term is meant to include C₁-C₁₂ alkyl groups havingan amino substituent at any position and wherein the alkyl groupattaches the aminoalkyl group to the parent molecule. The alkyl or aminoportions of the aminoalkyl group can be further substituted withsubstituent groups.

The term “aliphatic,” as used herein, refers to a straight or branchedhydrocarbon radical containing up to twenty four carbon atoms whereinthe saturation between any two carbon atoms is a single, double ortriple bond. An aliphatic group preferably contains from 1 to about 24carbon atoms, more typically from 1 to about 12 carbon atoms with from 1to about 6 carbon atoms being more preferred. The straight or branchedchain of an aliphatic group may be interrupted with one or moreheteroatoms that include nitrogen, oxygen, sulfur and phosphorus. Suchaliphatic groups, interrupted by heteroatoms include without limitationpolyalkoxys, such as polyalkylene glycols, polyamines, and polyimines.Aliphatic groups as used herein may optionally include furthersubstitutent groups.

The term “alicyclic” or “alicyclyl” refers to a cyclic ring systemwherein the ring is aliphatic. The ring system can comprise one or morerings wherein at least one ring is aliphatic. Preferred alicyclicsinclude rings having from about 5 to about 9 carbon atoms in the ring.Alicyclic as used herein may optionally include further substitutentgroups.

The term “alkoxy,” as used herein, refers to a radical formed between analkyl group and an oxygen atom wherein the oxygen atom is used to attachthe alkoxy group to a parent molecule. Examples of alkoxy groupsinclude, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy,n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy andthe like. Alkoxy groups as used herein may optionally include furthersubstitutent groups.

The terms “halo” and “halogen,” as used herein, refer to an atomselected from fluorine, chlorine, bromine and iodine.

The terms “aryl” and “aromatic,” as used herein, refer to a mono- orpolycyclic carbocyclic ring system radicals having one or more aromaticrings. Examples of aryl groups include, but are not limited to, phenyl,naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like. Preferredaryl ring systems have from about 5 to about 20 carbon atoms in one ormore rings. Aryl groups as used herein may optionally include furthersubstitutent groups.

The terms “aralkyl” and “arylalkyl,” as used herein, refer to a radicalformed between an alkyl group and an aryl group wherein the alkyl groupis used to attach the aralkyl group to a parent molecule. Examplesinclude, but are not limited to, benzyl, phenethyl and the like. Aralkylgroups as used herein may optionally include further substitutent groupsattached to the alkyl, the aryl or both groups that form the radicalgroup.

The term “heterocyclic radical” as used herein, refers to a radicalmono-, or poly-cyclic ring system that includes at least one heteroatomand is unsaturated, partially saturated or fully saturated, therebyincluding heteroaryl groups. Heterocyclic is also meant to include fusedring systems wherein one or more of the fused rings contain at least oneheteroatom and the other rings can contain one or more heteroatoms oroptionally contain no heteroatoms. A heterocyclic group typicallyincludes at least one atom selected from sulfur, nitrogen or oxygen.Examples of heterocyclic groups include, [1,3]dioxolane, pyrrolidinyl,pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl,piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl,isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl and thelike. Heterocyclic groups as used herein may optionally include furthersubstitutent groups.

The terms “heteroaryl,” and “heteroaromatic,” as used herein, refer to aradical comprising a mono- or poly-cyclic aromatic ring, ring system orfused ring system wherein at least one of the rings is aromatic andincludes one or more heteroatom. Heteroaryl is also meant to includefused ring systems including systems where one or more of the fusedrings contain no heteroatoms. Heteroaryl groups typically include onering atom selected from sulfur, nitrogen or oxygen. Examples ofheteroaryl groups include, but are not limited to, pyridinyl, pyrazinyl,pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl,isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl,isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, and thelike. Heteroaryl radicals can be attached to a parent molecule directlyor through a linking moiety such as an aliphatic group or hetero atom.Heteroaryl groups as used herein may optionally include furthersubstitutent groups.

The term “heteroarylalkyl,” as used herein, refers to a heteroaryl groupas previously defined having an alkyl radical that can attach theheteroarylalkyl group to a parent molecule. Examples include, but arenot limited to, pyridinylmethyl, pyrimidinylethyl, napthyridinylpropyland the like. Heteroarylalkyl groups as used herein may optionallyinclude further substitutent groups.

The term “mono or poly cyclic structure” as used herein includes allring systems that are single or polycyclic having rings that are fusedor linked and is meant to be inclusive of single and mixed ring systemsindividually selected from aliphatic, alicyclic, aryl, heteroaryl,aralkyl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic,heteroarylalkyl. Such mono and poly cyclic structures can contain ringsthat are uniform or have varying degrees of saturation including fullysaturated, partially saturated or fully unsaturated. Each ring cancomprise ring atoms selected from C, N, O and S to give rise toheterocyclic rings as well as rings comprising only C ring atoms whichcan be present in a mixed motif such as for example benzimidazolewherein one ring has only carbon ring atoms and the fused ring has twonitrogen atoms. The mono or poly cyclic structures can be furthersubstituted with substituent groups such as for example phthalimidewhich has two ═O groups attached to one of the rings. In another aspect,mono or poly cyclic structures can be attached to a parent moleculedirectly through a ring atom, through a substituent group or abifunctional linking moiety.

The term “acyl,” as used herein, refers to a radical formed by removalof a hydroxyl group from an organic acid and has the general formula—C(O)—X where X is typically aliphatic, alicyclic or aromatic. Examplesinclude aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls,aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates, aliphaticphosphates and the like. Acyl groups as used herein may optionallyinclude further substitutent groups. The term “oxo” refers to the group(═O).

The compounds described herein can be prepared by any of the applicabletechniques of organic synthesis, as, for example, illustrated in theexamples below. Many such techniques are well known in the art. However,many of the known techniques are elaborated in Compendium of OrganicSynthetic Methods (John Wiley & Sons, New York) Vol. 1, Ian T. Harrisonand Shuyen Harrison (1971); Vol. 2, Ian T. Harrison and Shuyen Harrison(1974); Vol. 3, Louis S. Hegedus and Leroy Wade (1977); Vol. 4, Leroy G.Wade Jr., (1980); Vol. 5, Leroy G. Wade Jr. (1984); and Vol. 6, MichaelB. Smith; as well as March, J., Advanced Organic Chemistry, 3rd Edition,John Wiley & Sons, New York (1985); Comprehensive Organic Synthesis.Selectivity, Strategy & Efficiency in Modern Organic Chemistry, In 9Volumes, Barry M. Trost, Editor-in-Chief, Pergamon Press, New York(1993); Advanced Organic Chemistry, Part B: Reactions and Synthesis, 4thEd.; Carey and Sundberg; Kluwer Academic/Plenum Publishers: New York(2001); Advanced Organic Chemistry, Reactions, Mechanisms, andStructure, 2nd Edition, March, McGraw Hill (1977); Greene's ProtectiveGroups in Organic Synthesis, 4th Edition, Greene, T. W., and Wutz, P. G.M., John Wiley & Sons, New York (2007); and Comprehensive OrganicTransformations, 2nd Edition, Larock, R. C., John Wiley & Sons, New York(1999).

In certain embodiments, oligomeric compounds provided herein aremodified by covalent attachment of one or more conjugate groups. Ingeneral, conjugate groups modify one or more properties of the attachedoligomeric compound including but not limited to pharmakodynamic,pharmacokinetic, binding, absorption, cellular distribution, cellularuptake, charge and clearance. Conjugate groups are routinely used in thechemical arts and are linked directly or via an optional linking moietyor linking group to a parent compound such as an oligomeric compound. Apreferred list of conjugate groups includes without limitation,intercalators, reporter molecules, drug groups such as ibuprofen,polyamines, polyamides, polyethylene glycols, thioethers, polyethers,cholesterols, thiocholesterols, cholic acid moieties, folate, lipids,phospholipids, biotin, phenazine, phenanthridine, anthraquinone,adamantane, acridine, fluoresceins, rhodamines, coumarins and dyes.

The term “protecting group,” as used herein, refers to a labile chemicalmoiety which is known in the art to protect reactive groups includingwithout limitation, hydroxyl, amino and thiol groups, against undesiredreactions during synthetic procedures. Protecting groups are typicallyused selectively and/or orthogonally to protect sites during reactionsat other reactive sites and can then be removed to leave the unprotectedgroup as is or available for further reactions. Protecting groups asknown in the art are described generally in Greene's Protective Groupsin Organic Synthesis, 4th Edition, Greene, T. W., and Wutz, P. G. M.,John Wiley & Sons, New York (2007).

Groups can be selectively incorporated into oligomeric compoundsprovided herein as precursors. For example an amino group can be placedinto a compound as an azido group that can be chemically converted tothe amino group at a desired point in the synthesis. Generally, groupsare protected or present as a precursor that will be inert to reactionsthat modify other areas of the parent molecule for conversion into theirfinal groups at an appropriate time. Further representative protectingor precursor groups are discussed in Agrawal, et al., Protocols forOligonucleotide Conjugates, Eds, Humana Press; New Jersey, 1994; Vol. 26pp. 1-72.

Examples of hydroxyl protecting groups include, but are not limited to,t-butyl, t-butoxymethyl, methoxymethyl, tetrahydropyranyl,1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 2-trimethylsilylethyl,p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl,diphenylmethyl, p-nitrobenzyl, bis(2-acetoxyethoxy)methyl (ACE),2-trimethylsilylethyl, triisopropylsilyl, [(triisopropylsilyl)oxymethyl(TOM), monomethoxytrityl, dimethoxytrityl (DMT), trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl (FPMP), 9-phenylxanthine-9-yl(Pixyl) and 9-(p-methoxyphenyl)xanthine-9-yl (MOX), triphenylmethyl(trityl), 4,4′-dimethoxytrityl, trimethylsilyl, triethylsilyl,t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl,benzoylformate, acetate, chloroacetate, trichloroacetate,trifluoroacetate, pivaloate, benzoate, p-phenylbenzoate,9-fluorenylmethyl carbonate, mesylate and tosylate. Where more preferredhydroxyl protecting groups include, but are not limited to, benzyl,2,6-dichlorobenzyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, benzoyl,mesylate, tosylate, dimethoxytrityl (DMT), 9-phenylxanthine-9-yl (Pixyl)and 9-(p-methoxyphenyl)xanthine-9-yl (MOX).

Examples of amino protecting groups include, but are not limited to,carbamate-protecting groups, such as 2-trimethylsilylethoxycarbonyl(Teoc), 1-methyl-1-(4-biphenylyl)ethoxycarbonyl (Bpoc), t-butoxycarbonyl(BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethyloxycarbonyl (Fmoc),and benzyloxycarbonyl (Cbz); amide-protecting groups, such as formyl,acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyl;sulfonamide-protecting groups, such as 2-nitrobenzenesulfonyl; andimine- and cyclic imide-protecting groups, such as phthalimido anddithiasuccinoyl.

Examples of thiol protecting groups include, but are not limited to,triphenylmethyl (trityl), benzyl (Bn), and the like.

In some preferred embodiments oligomeric compounds are prepared byconnecting nucleosides with optionally protected phosphorus containinginternucleoside linkages. Representative protecting groups forphosphorus containing internucleoside linkages such as phosphodiesterand phosphorothioate linkages include β-cyanoethyl, diphenylsilylethyl,δ-cyanobutenyl, cyano p-xylyl (CPX), N-methyl-N-trifluoroacetyl ethyl(META), acetoxy phenoxy ethyl (APE) and butene-4-yl groups. See forexample U.S. Pat. Nos. 4,725,677 and Re. 34,069 (β-cyanoethyl);Beaucage, S. L. and Iyer, R. P., Tetrahedron, 49 No. 10, pp. 1925-1963(1993); Beaucage, S. L. and Iyer, R. P., Tetrahedron, 49 No. 46, pp.10441-10488 (1993); Beaucage, S. L. and Iyer, R. P., Tetrahedron, 48 No.12, pp. 2223-2311 (1992).

As used herein, the term “orthogonally protected” refers to functionalgroups which are protected with different classes of protecting groups,wherein each class of protecting group can be removed in any order andin the presence of all other classes (see, Barany, G. and Merrifield, R.B., J. Am. Chem. Soc., 1977, 99, 7363; idem, 1980, 102, 3084.)Orthogonal protection is widely used in for example automatedoligonucleotide synthesis. A functional group is deblocked in thepresence of one or more other protected functional groups which is notaffected by the deblocking procedure. This deblocked functional group isreacted in some manner and at some point a further orthogonal protectinggroup is removed under a different set of reaction conditions. Thisallows for selective chemistry to arrive at a desired Compound oroligomeric Compound.

In certain embodiments, provided herein are compounds having reactivephosphorus groups useful for forming internucleoside linkages includingfor example phosphodiester and phosphorothioate internucleosidelinkages. Such reactive phosphorus groups are known in the art andcontain phosphorus atoms in P^(III) or P^(V) valence state including,but not limited to, phosphoramidite, H-phosphonate, phosphate triestersand phosphorus containing chiral auxiliaries. A preferred syntheticsolid phase synthesis utilizes phosphoramidites (P^(III) chemistry) asreactive phosphites. The intermediate phosphite compounds aresubsequently oxidized to the P^(V) state using known methods to yield,in preferred embodiments, phosphodiester or phosphorothioateinternucleotide linkages. Additional reactive phosphates and phosphitesare disclosed in Tetrahedron Report Number 309 (Beaucage and Iyer,Tetrahedron, 1992, 48, 2223-2311).

As used herein the term “internucleoside linkage” or “internucleosidelinking group” is meant to include all manner of internucleoside linkinggroups known in the art including but not limited to, phosphoruscontaining internucleoside linking groups such as phosphodiester andphosphorothioate, non-phosphorus containing internucleoside linkinggroups such as formacetyl and methyleneimino, and neutral non-ionicinternucleoside linking groups such as amide-3 (3′-CH₂—C(═O)—N(H)-5′),amide-4 (3′-CH₂—N(H)—C(═O)-5′).

Specific examples of oligomeric compounds useful herein includeoligonucleotides containing modified e.g. non-naturally occurringinternucleoside linkages. Two main classes of internucleoside linkagesare defined by the presence or absence of a phosphorus atom. Modifiedinternucleoside linkages having a phosphorus atom include, but are notlimited to, phosphorothioates, chiral phosphorothioates,phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters,methyl and other alkyl phosphonates including 3′-alkylene phosphonates,5′-alkylene phosphonates and chiral phosphonates, phosphinates,phosphoramidates including 3′-amino phosphoramidate andaminoalkylphosphoramidates, thionophosphoramidates,thionoalkylphos-phonates, thionoalkylphosphotriesters, selenophosphatesand boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogsof these, and those having inverted polarity wherein one or moreinternucleotide linkages is a 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage.Oligonucleotides having inverted polarity can comprise a single 3′ to 3′linkage at the 3′-most internucleotide linkage i.e. a single invertednucleoside residue which may be abasic (the nucleobase is missing or hasa hydroxyl group in place thereof). Various salts, mixed salts and freeacid forms are also included.

Representative U.S. patents that teach the preparation of the abovephosphorus-containing linkages include, but are not limited to, U.S.Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196;5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131;5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925;5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799;5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and5,625,050, certain of which are commonly owned with this application,and each of which is herein incorporated by reference.

Modified internucleoside linkages not having a phosphorus atom include,but are not limited to, those that are formed by short chain alkyl orcycloalkyl internucleoside linkages, mixed heteroatom and alkyl orcycloalkyl internucleoside linkages, or one or more short chainheteroatomic or heterocyclic internucleoside linkages. These includethose having siloxane backbones; sulfide, sulfoxide and sulfonebackbones; formacetyl and thioformacetyl backbones; methylene formacetyland thioformacetyl backbones; riboacetyl backbones; alkene containingbackbones; sulfamate backbones; methyleneimino and methylenehydrazinobackbones; sulfonate and sulfonamide backbones; amide backbones; andothers having mixed N, O, S and CH₂ component parts.

Representative U.S. patents that teach the preparation of the aboveoligonucleosides include, but are not limited to, U.S. Pat. Nos.5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033;5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967;5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312;5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain ofwhich are commonly owned with this application, and each of which isherein incorporated by reference.

The compounds described herein contain one or more asymmetric centersand thus give rise to enantiomers, diastereomers, and otherstereoisomeric forms that may be defined, in terms of absolutestereochemistry, as (R)- or (S)-, α or β, or as (D)- or (L)- such as foramino acids et al. Included herein are all such possible isomers, aswell as their racemic and optically pure forms. Optical isomers may beprepared from their respective optically active precursors by theprocedures described above, or by resolving the racemic mixtures. Theresolution can be carried out in the presence of a resolving agent, bychromatography or by repeated crystallization or by some combination ofthese techniques which are known to those skilled in the art. Furtherdetails regarding resolutions can be found in Jacques, et al.,Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). Whenthe compounds described herein contain olefinic double bonds, otherunsaturation, or other centers of geometric asymmetry, and unlessspecified otherwise, it is intended that the compounds include both Eand Z geometric isomers or cis- and trans-isomers. Likewise, alltautomeric forms are also intended to be included. The configuration ofany carbon-carbon double bond appearing herein is selected forconvenience only and is not intended to designate a particularconfiguration unless the text so states; thus a carbon-carbon doublebond or carbon-heteroatom double bond depicted arbitrarily herein astrans may be cis, trans, or a mixture of the two in any proportion.

In certain embodiments, the term “oligomeric compound” refers to apolymer having at least a region that is capable of hybridizing to anucleic acid molecule. The term “oligomeric compound” includesoligonucleotides, oligonucleotide analogs and oligonucleosides as wellas nucleotide mimetics and/or mixed polymers comprising nucleic acid andnon-nucleic acid components. Oligomeric compounds are routinely preparedlinearly but can be joined or otherwise prepared to be circular and mayalso include branching. Oligomeric compounds can form double strandedconstructs such as for example two strands hybridized to form doublestranded compositions. The double stranded compositions can be linked orseparate and can include overhangs on the ends. In general, anoligomeric compound comprises a backbone of linked monomeric subunitswhere each linked monomeric subunit is directly or indirectly attachedto a heterocyclic base moiety. Oligomeric compounds may also includemonomeric subunits that are not linked to a heterocyclic base moietythereby providing abasic sites. The linkages joining the monomericsubunits, the sugar moieties or surrogates and the heterocyclic basemoieties can be independently modified. The linkage-sugar unit, whichmay or may not include a heterocyclic base, may be substituted with amimetic such as the monomers in peptide nucleic acids. The ability tomodify or substitute portions or entire monomers at each position of anoligomeric compound gives rise to a large number of possible motifs.

In certain embodiments, the term “oligomeric compound” refers to acontiguous sequence of linked monomeric subunits. In general each linkedmonomeric subunits is directly or indirectly attached to a heterocyclicbase moiety but abasic sites are also possible. At least some andgenerally most if not essentially all of the heterocyclic bases in anoligomeric compound are capable of hybridizing to a nucleic acidmolecule, normally a preselected RNA target. The term “oligomericcompound” therefore includes oligonucleotides, oligonucleotide analogsand oligonucleosides. It also includes polymers having a plurality ofnon-naturally occurring nucleoside mimetics and or nucleosides havingsugar surrogate groups. When preparing oligomeric compounds havingspecific motifs as disclosed herein it can be advantageous to mixnon-naturally occurring monomer subunits such as the bis-modifiedbicyclic nucleosides as provided herein with other non-naturallyoccurring monomer subunits, naturally occurring monomer subunits(nucleosides) or mixtures thereof. In certain embodiments, oligomericcompounds are provided herein comprising a contiguous sequence of linkedmonomeric subunits wherein at least one monomeric subunit is abis-modified bicyclic nucleoside as provided herein. In certainembodiments, oligomeric compounds are provided comprising a plurality ofbis-modified bicyclic nucleosides as provided herein.

As is known in the art, a nucleoside is a base-sugar combination. Thebase portion of the nucleoside is normally a heterocyclic base moiety.The two most common classes of such heterocyclic bases are purines andpyrimidines. Nucleotides are nucleosides that further include aphosphate group covalently linked to the sugar portion of thenucleoside. For those nucleosides that include a pentofuranosyl sugar,the phosphate group can be linked to either the 2′, 3′ or 5′ hydroxylmoiety of the sugar. In forming oligonucleotides, the phosphate groupscovalently link adjacent nucleosides to one another to form a linearpolymeric compound. The respective ends of this linear polymericstructure can be joined to form a circular structure by hybridization orby formation of a covalent bond however, open linear structures aregenerally desired. Within the oligonucleotide structure, the phosphategroups are commonly referred to as forming the internucleoside linkagesof the oligonucleotide. The normal internucleoside linkage of RNA andDNA is a 3′ to 5′ phosphodiester linkage.

In certain embodiments, the term “oligonucleotide” refers to an oligomeror polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA).This term includes oligonucleotides composed of naturally-occurringnucleobases, sugars and covalent internucleoside linkages. The term“oligonucleotide analog” refers to oligonucleotides that have one ormore non-naturally occurring portions. Such non-naturally occurringoligonucleotides are often desired over naturally occurring formsbecause of desirable properties such as, for example, enhanced cellularuptake, enhanced affinity for nucleic acid target and increasedstability in the presence of nucleases.

In certain embodiments, the term “oligonucleoside” refers to a sequenceof nucleosides that are joined by internucleoside linkages that do nothave phosphorus atoms. Internucleoside linkages of this type includeshort chain alkyl, cycloalkyl, mixed heteroatom alkyl, mixed heteroatomcycloalkyl, one or more short chain heteroatomic and one or more shortchain heterocyclic. These internucleoside linkages include, but are notlimited to, siloxane, sulfide, sulfoxide, sulfone, acetyl, formacetyl,thioformacetyl, methylene formacetyl, thioformacetyl, alkenyl,sulfamate; methyleneimino, methylenehydrazino, sulfonate, sulfonamide,amide and others having mixed N, O, S and CH₂ component parts.

Representative U.S. patents that teach the preparation of the aboveoligonucleosides include, but are not limited to, U.S. Pat. Nos.5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033;5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967;5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312;5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain ofwhich are commonly owned with this application, and each of which isherein incorporated by reference.

The term “nucleobase” or “heterocyclic base moiety” as used herein, isintended to by synonymous with “nucleic acid base or mimetic thereof.”In general, a nucleobase is any substructure that contains one or moreatoms or groups of atoms capable of hydrogen bonding to a base of anucleic acid. The term heterocyclic base moiety includes, purines,pyrimidines, heterocyclic bases, modified bases, modified nucleobasesand natural and non-naturally occurring nucleobases.

As used herein, “unmodified” or “natural” nucleobases include the purinebases adenine (A) and guanine (G), and the pyrimidine bases thymine (T),cytosine (C) and uracil (U). Modified nucleobases include, but are notlimited to other synthetic and natural nucleobases such as for example5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine,hypoxanthine and 2-aminoadenine. Modified nucleobases may also includethose in which the purine or pyrimidine base is replaced with otherheterocycles, for example 7-deaza-adenine, 7-deazaguanosine,2-aminopyridine and 2-pyridone. Further nucleobases include thosedisclosed in U.S. Pat. No. 3,687,808, those disclosed in The ConciseEncyclopedia Of Polymer Science And Engineering, pages 858-859,Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed byEnglisch et al, Angewandte Chemie, International Edition, 1991, 30, 613,and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Researchand Applications, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRCPress, 1993.

Modified nucleobases include, but are not limited to, universal bases,hydrophobic bases, promiscuous bases, size-expanded bases, andfluorinated bases as defined herein. Certain of these nucleobases areparticularly useful for increasing the binding affinity of theoligomeric compounds provided herein. These include 5-substitutedpyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines,including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.5-methylcytosine substitutions have been shown to increase nucleic acidduplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. andLebleu, B., eds., Antisense Research and Applications, CRC Press, BocaRaton, 1993, pp. 276-278) and are presently preferred basesubstitutions, even more particularly when combined with2′-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation ofcertain of the above noted modified nucleobases as well as othermodified nucleobases include, but are not limited to, the above notedU.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302;5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255;5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121,5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and5,681,941, certain of which are commonly owned with the instantapplication, and each of which is herein incorporated by reference, andU.S. Pat. No. 5,750,692, which is commonly owned with the instantapplication and also herein incorporated by reference.

In addition to having at least one bis-modified bicyclic nucleoside,oligomeric compounds provided herein may also contain one or moreadditional nucleosides having modified sugar moieties. The furanosylsugar ring can be modified in a number of ways including substitutionwith a substituent group, bridging to form a BNA and substitution of the4′-O with a heteroatom such as S or N(R). Some representative U.S.patents that teach the preparation of such modified sugars include, butare not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080;5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134;5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053;5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; 5,700,920,6,600,032 and International Application PCT/US2005/019219, filed Jun. 2,2005 and published as WO 2005/121371 on Dec. 22, 2005 certain of whichare commonly owned with the instant application, and each of which isherein incorporated by reference in its entirety. A representative listof preferred modified sugars includes but is not limited to substitutedsugars having a 2′-F, 2′-OCH₂ or a 2′-O(CH₂)₂—OCH₃ substituent group;4′-thio modified sugars and bicyclic modified sugars.

In certain embodiments, the oligomeric compounds provided herein mayalso contain one or more nucleosides having modified sugar moieties. Thefuranosyl sugar ring can be modified in a number of ways includingsubstitution with a substituent group, bridging to form a BNA andsubstitution of the 4′-O with a heteroatom such as S or N(R). Somerepresentative U.S. patents that teach the preparation of such modifiedsugars include, but are not limited to, U.S. Pat. Nos. 4,981,957;5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786;5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909;5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633;5,792,747; 5,700,920; 6,600,032 and International ApplicationPCT/US2005/019219, filed Jun. 2, 2005 and published as WO 2005/121371 onDec. 22, 2005 certain of which are commonly owned with the instantapplication, and each of which is herein incorporated by reference inits entirety. A representative list of preferred modified sugarsincludes but is not limited to substituted sugars having a 2′-F, 2′-OCH₂or a 2′-O(CH₂)₂—OCH₃ substituent group; 4′-thio modified sugars andbicyclic modified sugars.

As used herein the term “nucleoside mimetic” is intended to includethose structures used to replace the sugar or the sugar and the base notthe linkage at one or more positions of an oligomeric compound such asfor example nucleoside mimetics having morpholino or bicyclo[3.1.0]hexylsugar mimetics e.g. non furanose sugar units with a phosphodiesterlinkage. The term “sugar surrogate” overlaps with the slightly broaderterm “nucleoside mimetic” but is intended to indicate replacement of thesugar unit (furanose ring) only. The term “nucleotide mimetic” isintended to include those structures used to replace the nucleoside andthe linkage at one or more positions of an oligomeric compound such asfor example peptide nucleic acids or morpholinos (morpholinos linked by—N(H)—C(═O)—O— or other non-phosphodiester linkage.

In certain embodiments, oligomeric compounds provided herein cancomprise from about 8 to about 80 nucleosides and/or modifiednucleosides or mimetics in length. One of ordinary skill in the art willappreciate that the invention embodies oligomeric compounds of 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64,65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80nucleosides and/or modified nucleosides or mimetics in length, or anyrange therewithin.

In certain embodiments, the oligomeric compounds of the invention are 8to 40 nucleosides and/or modified nucleosides or mimetics in length. Onehaving ordinary skill in the art will appreciate that this embodiesoligomeric compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38, 39 or 40 nucleosides and/or modified nucleosides or mimetics inlength, or any range therewithin.

In certain embodiments, the oligomeric compounds provided herein are 8to 20 nucleosides and/or modified nucleosides or mimetics in length. Onehaving ordinary skill in the art will appreciate that this embodiesoligomeric compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or20 nucleosides and/or modified nucleosides or mimetics in length, or anyrange therewithin.

In certain embodiments, the oligomeric compounds provided herein are 10to 16 nucleosides and/or modified nucleosides or mimetics in length. Onehaving ordinary skill in the art will appreciate that this embodiesoligomeric compounds of 10, 11, 12, 13, 14, 15 or 16 nucleosides and/ormodified nucleosides or mimetics in length, or any range therewithin.

In certain embodiments, the oligomeric compounds provided herein are 10to 14 nucleosides and/or modified nucleosides or mimetics in length. Onehaving ordinary skill in the art will appreciate that this embodiesoligomeric compounds of 10, 11, 12, 13 or 14 nucleosides and/or modifiednucleosides or mimetics in length, or any range therewithin.

In certain embodiments, oligomeric compounds provided herein comprisefrom about 12 to 16 monomer subunits in length. One having ordinaryskill in the art will appreciate that this embodies oligomeric compoundsof 12, 13, 14, 15 or 16 monomer subunits in length, or any rangetherewithin.

In certain embodiments, oligomeric compounds of any of a variety ofranges of lengths of linked monomer subunits are provided. In certainembodiments, oligomeric compounds are provided consisting of X-Y linkedmonomer subunits, where X and Y are each independently selected from8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,45, 46, 47, 48, 49, and 50; provided that X<Y. For example, in certainembodiments, the invention provides oligomeric compounds comprising:8-9, 8-10, 8-11, 8-12, 8-13, 8-14, 8-15, 8-16, 8-17, 8-18, 8-19, 8-20,8-21, 8-22, 8-23, 8-24, 8-25, 8-26, 8-27, 8-28, 8-29, 8-30, 9-10, 9-11,9-12, 9-13, 9-14, 9-15, 9-16, 9-17, 9-18, 9-19, 9-20, 9-21, 9-22, 9-23,9-24, 9-25, 9-26, 9-27, 9-28, 9-29, 9-30, 10-11, 10-12, 10-13, 10-14,10-15, 10-16, 10-17, 10-18, 10-19, 10-20, 10-21, 10-22, 10-23, 10-24,10-25, 10-26, 10-27, 10-28, 10-29, 10-30, 11-12, 11-13, 11-14, 11-15,11-16, 11-17, 11-18, 11-19, 11-20, 11-21, 11-22, 11-23, 11-24, 11-25,11-26, 11-27, 11-28, 11-29, 11-30, 12-13, 12-14, 12-15, 12-16, 12-17,12-18, 12-19, 12-20, 12-21, 12-22, 12-23, 12-24, 12-25, 12-26, 12-27,12-28, 12-29, 12-30, 13-14, 13-15, 13-16, 13-17, 13-18, 13-19, 13-20,13-21, 13-22, 13-23, 13-24, 13-25, 13-26, 13-27, 13-28, 13-29, 13-30,14-15, 14-16, 14-17, 14-18, 14-19, 14-20, 14-21, 14-22, 14-23, 14-24,14-25, 14-26, 14-27, 14-28, 14-29, 14-30, 15-16, 15-17, 15-18, 15-19,15-20, 15-21, 15-22, 15-23, 15-24, 15-25, 15-26, 15-27, 15-28, 15-29,15-30, 16-17, 16-18, 16-19, 16-20, 16-21, 16-22, 16-23, 16-24, 16-25,16-26, 16-27, 16-28, 16-29, 16-30, 17-18, 17-19, 17-20, 17-21, 17-22,17-23, 17-24, 17-25, 17-26, 17-27, 17-28, 17-29, 17-30, 18-19, 18-20,18-21, 18-22, 18-23, 18-24, 18-25, 18-26, 18-27, 18-28, 18-29, 18-30,19-20, 19-21, 19-22, 19-23, 19-24, 19-25, 19-26, 19-29, 19-28, 19-29,19-30, 20-21, 20-22, 20-23, 20-24, 20-25, 20-26, 20-27, 20-28, 20-29,20-30, 21-22, 21-23, 21-24, 21-25, 21-26, 21-27, 21-28, 21-29, 21-30,22-23, 22-24, 22-25, 22-26, 22-27, 22-28, 22-29, 22-30, 23-24, 23-25,23-26, 23-27, 23-28, 23-29, 23-30, 24-25, 24-26, 24-27, 24-28, 24-29,24-30, 25-26, 25-27, 25-28, 25-29, 25-30, 26-27, 26-28, 26-29, 26-30,27-28, 27-29, 27-30, 28-29, 28-30, or 29-30 linked monomer subunits.

In certain embodiments, ranges for the length of the oligomericcompounds provided herein are 8-16, 8-40, 10-12, 10-14, 10-16, 10-18,10-20, 10-21, 12-14, 12-16, 12-18, 12-20 and 12-24 linked monomersubunits.

In certain embodiments, the ranges for the oligomeric compounds listedherein are meant to limit the number of monomer subunits in theoligomeric compounds, however such oligomeric compounds may furtherinclude protecting groups such as hydroxyl protecting groups, optionallylinked conjugate groups, 5′ and/or 3′-terminal groups and/or othersubstituents.

In certain embodiments, the oligomerization of modified and unmodifiednucleosides and mimetics thereof is performed according to literatureprocedures for DNA (Protocols for Oligonucleotides and Analogs, Ed.Agrawal (1993), Humana Press) and/or RNA (Scaringe, Methods (2001), 23,206-217; Gait et al., Applications of Chemically synthesized RNA inRNA:Protein Interactions, Ed. Smith (1998), 1-36; Gallo et al.,Tetrahedron (2001), 57, 5707-5713) synthesis as appropriate. Additionalmethods for solid-phase synthesis may be found in Caruthers U.S. Pat.Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and5,132,418; and Koster U.S. Pat. Nos. 4,725,677 and Re. 34,069.

Commercially available equipment routinely used for the support mediumbased synthesis of oligomeric compounds and related compounds is sold byseveral vendors including, for example, Applied Biosystems (Foster City,Calif.). Any other means for such synthesis known in the art mayadditionally or alternatively be employed. Suitable solid phasetechniques, including automated synthesis techniques, are described inF. Eckstein (ed.), Oligonucleotides and Analogues, a Practical Approach,Oxford University Press, New York (1991).

The synthesis of RNA and related analogs relative to the synthesis ofDNA and related analogs has been increasing as efforts in RNAi increase.The primary RNA synthesis strategies that are presently being usedcommercially include 5′-O-DMT-2′-O-t-butyldimethylsilyl (TBDMS),5′-O-DMT-2′-O-[1 (2-fluorophenyl)-4-methoxypiperidin-4-yl] (FPMP),2′-O-[(triisopropylsilyl)oxy]methyl (2′-O—CH₂—O—Si(iPr)₃ (TOM), and the5′-O-silyl ether-2′-ACE (5′-O-bis(trimethylsiloxy)cyclododecyloxysilylether (DOD)-2′-O-bis(2-acetoxyethoxy)methyl (ACE). A current list ofsome of the major companies currently offering RNA products includePierce Nucleic Acid Technologies, Dharmacon Research Inc., AmeriBiotechnologies Inc., and Integrated DNA Technologies, Inc. One company,Princeton Separations, is marketing an RNA synthesis activatoradvertised to reduce coupling times especially with TOM and TBDMSchemistries. Such an activator would also be amenable herein.

The primary groups being used for commercial RNA synthesis are:

-   -   TBDMS=5′-O-DMT-2′-O-t-butyldimethylsilyl;    -   TOM=2′-O-[(triisopropylsilyl)oxy]methyl;    -   DOD/ACE=(5′-O-bis(trimethylsiloxy)cyclododecyloxysilyl        ether-2′-O-bis(2-acetoxyethoxy)methyl    -   FPMP=5′-O-DMT-2′-O-[1(2-fluorophenyl)-4-methoxypiperidin-4-yl].

All of the aforementioned RNA synthesis strategies are amenable herein.Strategies that would be a hybrid of the above e.g. using a5′-protecting group from one strategy with a 2′-O-protecting fromanother strategy is also amenable herein.

In certain embodiments, “hybridization” means the pairing ofcomplementary strands of oligomeric compounds. In certain embodiments,one mechanism of pairing involves hydrogen bonding, which may beWatson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, betweencomplementary nucleoside or nucleotide bases (nucleobases) of thestrands of oligomeric compounds. For example, adenine and thymine arecomplementary nucleobases which pair through the formation of hydrogenbonds. Hybridization can occur under varying circumstances.

An oligomeric compound is specifically hybridizable when binding of thecompound to the target nucleic acid interferes with the normal functionof the target nucleic acid to cause a loss of activity, and there is asufficient degree of complementarity to avoid non-specific binding ofthe oligomeric compound to non-target nucleic acid sequences underconditions in which specific binding is desired, i.e., underphysiological conditions in the case of in vivo assays or therapeutictreatment, and under conditions in which assays are performed in thecase of in vitro assays.

“Complementary,” as used herein, refers to the capacity for precisepairing of two nucleobases regardless of where the two are located. Forexample, if a nucleobase at a certain position of an oligomeric compoundis capable of hydrogen bonding with a nucleobase at a certain positionof a target nucleic acid, the target nucleic acid being a DNA, RNA, oroligonucleotide molecule, then the position of hydrogen bonding betweenthe oligonucleotide and the target nucleic acid is considered to be acomplementary position. The oligomeric compound and the further DNA,RNA, or oligonucleotide molecule are complementary to each other when asufficient number of complementary positions in each molecule areoccupied by nucleobases which can hydrogen bond with each other. Thus,“specifically hybridizable” and “complementary” are terms which are usedto indicate a sufficient degree of precise pairing or complementarityover a sufficient number of nucleobases such that stable and specificbinding occurs between the oligonucleotide and a target nucleic acid.

It is understood in the art that the sequence of an oligomeric compoundneed not be 100% complementary to that of its target nucleic acid to bespecifically hybridizable. Moreover, an oligonucleotide may hybridizeover one or more segments such that intervening or adjacent segments arenot involved in the hybridization event (e.g., a loop structure orhairpin structure). The oligomeric compounds provided herein cancomprise at least about 70%, at least about 80%, at least about 90%, atleast about 95%, or at least about 99% sequence complementarity to atarget region within the target nucleic acid sequence to which they aretargeted. For example, an oligomeric compound in which 18 of 20nucleobases of the oligomeric compound are complementary to a targetregion, and would therefore specifically hybridize, would represent 90percent complementarity. In this example, the remaining noncomplementarynucleobases may be clustered or interspersed with complementarynucleobases and need not be contiguous to each other or to complementarynucleobases. As such, an oligomeric compound which is 18 nucleobases inlength having 4 (four) noncomplementary nucleobases which are flanked bytwo regions of complete complementarity with the target nucleic acidwould have 77.8% overall complementarity with the target nucleic acidand would thus fall within the scope of the present disclosure. Percentcomplementarity of an oligomeric compound with a region of a targetnucleic acid can be determined routinely using BLAST programs (basiclocal alignment search tools) and PowerBLAST programs known in the art(Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden,Genome Res., 1997, 7, 649-656).

Further included herein are oligomeric compounds such as antisenseoligomeric compounds, antisense oligonucleotides, ribozymes, externalguide sequence (EGS) oligonucleotides, alternate splicers, primers,probes, and other oligomeric compounds which hybridize to at least aportion of the target nucleic acid. As such, these oligomeric compoundsmay be introduced in the form of single-stranded, double-stranded,circular or hairpin oligomeric compounds and may contain structuralelements such as internal or terminal bulges or loops. Once introducedto a system, the oligomeric compounds provided herein may elicit theaction of one or more enzymes or structural proteins to effectmodification of the target nucleic acid.

In certain embodiments, single stranded oligomers are provided thathybridize to a nucleic acid target and degrade the target by recruitmentof an endonuclease enzyme. One non-limiting example of such an enzyme isRNAse H, a cellular endonuclease which cleaves the RNA strand of anRNA:DNA duplex. It is known in the art that single-stranded oligomericcompounds which are “DNA-like” elicit RNAse H. Activation of RNase H,therefore, results in cleavage of the RNA target, thereby greatlyenhancing the efficiency of oligonucleotide-mediated inhibition of geneexpression. Similar roles have been postulated for other ribonucleasessuch as those in the RNase III and ribonuclease L family of enzymes.

While one form of oligomeric compound is a single-stranded antisenseoligonucleotide, in many species the introduction of double-strandedstructures, such as double-stranded RNA (dsRNA) molecules, has beenshown to induce potent and specific antisense-mediated reduction of thefunction of a gene or its associated gene products. This phenomenonoccurs in both plants and animals and is believed to have anevolutionary connection to viral defense and transposon silencing.

In some embodiments, “suitable target segments” may be employed in ascreen for additional oligomeric compounds that modulate the expressionof a selected protein. “Modulators” are those oligomeric compounds thatdecrease or increase the expression of a nucleic acid molecule encodinga protein and which comprise at least an 8-nucleobase portion which iscomplementary to a suitable target segment. The screening methodcomprises the steps of contacting a suitable target segment of a nucleicacid molecule encoding a protein with one or more candidate modulators,and selecting for one or more candidate modulators which decrease orincrease the expression of a nucleic acid molecule encoding a protein.Once it is shown that the candidate modulator or modulators are capableof modulating (e.g. either decreasing or increasing) the expression of anucleic acid molecule encoding a peptide, the modulator may then beemployed in further investigative studies of the function of thepeptide, or for use as a research, diagnostic, or therapeutic agent inaccordance with the present disclosure.

In certain embodiments, suitable target segments may also be combinedwith their respective complementary antisense oligomeric compounds toform stabilized double-stranded (duplexed) oligonucleotides. Such doublestranded oligonucleotide moieties have been shown in the art to modulatetarget expression and regulate translation as well as RNA processing viaan antisense mechanism. Moreover, the double-stranded moieties may besubject to chemical modifications (Fire et al., Nature, 1998, 391,806-811; Timmons and Fire, Nature 1998, 395, 854; Timmons et al., Gene,2001, 263, 103-112; Tabara et al., Science, 1998, 282, 430-431;Montgomery et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 15502-15507;Tuschl et al., Genes Dev., 1999, 13, 3191-3197; Elbashir et al., Nature,2001, 411, 494-498; Elbashir et al., Genes Dev. 2001, 15, 188-200). Forexample, such double-stranded moieties have been shown to inhibit thetarget by the classical hybridization of antisense strand of the duplexto the target, thereby triggering enzymatic degradation of the target(Tijsterman et al., Science, 2002, 295, 694-697).

The oligomeric compounds provided herein can also be applied in theareas of drug discovery and target validation. In certain embodiments,the use of the oligomeric compounds and targets identified herein indrug discovery efforts to elucidate relationships that exist betweenproteins and a disease state, phenotype, or condition are provided.These methods include detecting or modulating a target peptidecomprising contacting a sample, tissue, cell, or organism with theoligomeric compounds provided herein, measuring the nucleic acid orprotein level of the target and/or a related phenotypic or chemicalendpoint at some time after treatment, and optionally comparing themeasured value to a non-treated sample or sample treated with a furtheroligomeric compound provided herein. These methods can also be performedin parallel or in combination with other experiments to determine thefunction of unknown genes for the process of target validation or todetermine the validity of a particular gene product as a target fortreatment or prevention of a particular disease, condition, orphenotype.

Effect of nucleoside modifications on RNAi activity is evaluatedaccording to existing literature (Elbashir et al., Nature (2001), 411,494-498; Nishikura et al., Cell (2001), 107, 415-416; and Bass et al.,Cell (2000), 101, 235-238.)

The oligomeric compounds provided herein can be utilized fordiagnostics, therapeutics, prophylaxis and as research reagents andkits. Furthermore, antisense oligonucleotides, which are able to inhibitgene expression with exquisite specificity, are often used by those ofordinary skill to elucidate the function of particular genes or todistinguish between functions of various members of a biologicalpathway. The oligomeric compounds provided herein, either alone or incombination with other oligomeric compounds or therapeutics, can be usedas tools in differential and/or combinatorial analyses to elucidateexpression patterns of a portion or the entire complement of genesexpressed within cells and tissues. Oligomeric compounds can also beeffectively used as primers and probes under conditions favoring geneamplification or detection, respectively. These primers and probes areuseful in methods requiring the specific detection of nucleic acidmolecules encoding proteins and in the amplification of the nucleic acidmolecules for detection or for use in further studies. Hybridization ofthe antisense oligonucleotides, particularly the primers and probes,with a nucleic acid can be detected by means known in the art. Suchmeans may include conjugation of an enzyme to the oligonucleotide,radiolabelling of the oligonucleotide or any other suitable detectionmeans. Kits using such detection means for detecting the level ofselected proteins in a sample may also be prepared.

As one nonlimiting example, expression patterns within cells or tissuestreated with one or more oligomeric compounds are compared to controlcells or tissues not treated with oligomeric compounds and the patternsproduced are analyzed for differential levels of gene expression as theypertain, for example, to disease association, signaling pathway,cellular localization, expression level, size, structure or function ofthe genes examined. These analyses can be performed on stimulated orunstimulated cells and in the presence or absence of other compounds andor oligomeric compounds which affect expression patterns.

Examples of methods of gene expression analysis known in the art includeDNA arrays or microarrays (Brazma and Vilo, FEBS Lett., 2000, 480,17-24; Celis, et al., FEBS Lett., 2000, 480, 2-16), SAGE (serialanalysis of gene expression)(Madden, et al., Drug Discov. Today, 2000,5, 415-425), READS (restriction enzyme amplification of digested cDNAs)(Prashar and Weissman, Methods Enzymol., 1999, 303, 258-72), TOGA (totalgene expression analysis) (Sutcliffe, et al., Proc. Natl. Acad. Sci.U.S.A., 2000, 97, 1976-81), protein arrays and proteomics (Celis, etal., FEBS Lett., 2000, 480, 2-16; Jungblut, et al., Electrophoresis,1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, etal., FEBS Lett., 2000, 480, 2-16; Larsson, et al., J. Biotechnol., 2000,80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., Anal.Biochem., 2000, 286, 91-98; Larson, et al., Cytometry, 2000, 41,203-208), subtractive cloning, differential display (DD) (Jurecic andBelmont, Curr. Opin. Microbiol., 2000, 3, 316-21), comparative genomichybridization (Carulli, et al., J. Cell Biochem. Suppl., 1998, 31,286-96), FISH (fluorescent in situ hybridization) techniques (Going andGusterson, Eur. J. Cancer, 1999, 35, 1895-904) and mass spectrometrymethods (To, Comb. Chem. High Throughput Screen, 2000, 3, 235-41).

While in certain embodiments, the bis-modified bicyclic nucleosides andoligomeric compounds that can be prepared therefrom provided herein canbe utilized as described, the following examples serve only toillustrate and are not intended to be limiting.

Example 1 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane(19a)

A) Preparation of Compound 4

A solution of tert-butyldimethylsilylchloride (6.24 g, 40.7 mmol) indichloromethane (10 mL) was added over 10 min, via an addition funnel,to a cold (0° C.) solution of Compound 2 (12 g, 38.8 mmol, preparedaccording to the procedure of Moffatt et al, J. Org. Chem. 1979, 44,1301), triethylamine (11.44 mL, 81.5 mmol) and4-dimethylaminoethylpyridine (0.47 g, 3.9 mmol) in CH₂Cl₂ (184 mL).After the addition was complete, the reaction was gradually warmed toroom temperature and stirred for an additional 16 hours. The reactionwas diluted with CH₂Cl₂ and sequentially washed with 5% aqueous HCl,saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated under vacuum.Purification by column chromatography (SiO₂, eluting with 10%EtOAc/hexanes-20% EtOAc/hexanes-30% EtOAc/hexanes) gave Compound 3(11.53 g, 59%) and Compound 4 (3.93 g, 22%) as white solids.

B) Preparation of Compound 5

Dimethylsulfoxide (1.84 mL, 26.0 mmol) was added to a cold (−78° C.)solution of oxalyl chloride (1.14 mL, 13.0 mmol) in CH₂Cl₂ (70 mL). Thesolution was stirred at −78° C. for 30 minutes and a solution ofCompound 4 (3.93 g, 9.3 mmol) in CH₂Cl₂ (20 mL) was added via a cannula.The stirring was continued for 45 minutes and triethylamine (5.48 mL,39.0 mmol) was added to the reaction. The reaction was stirred for anadditional 40 minutes after which it was poured into CH₂Cl₂ and theorganic layer was sequentially washed with 5% aqueous HCl, saturatedNaHCO₃, brine, dried (Na₂SO₄) and concentrated under vacuum to provideCompound 5, which was used without purification in the next step.

C) Preparation of Compound 6a and Compound 6b

A suspension of cerium III chloride (4.57 g, 18.6 mmol) in THF (55 mL)was stirred at room temperature for 90 minutes. The reaction was cooledin an ice bath and methyl magnesium bromide (13.3 mL of a 1M solution inTHF) was added over 5 minutes and the stirring continued for another 90minutes. A solution of crude Compound 5 (from above) in THF (15 mL) wasadded to the reaction. After stirring for another 90 minutes, thereaction was quenched with sat NH₄Cl solution and poured into EtOAc. Theorganic layer was sequentially washed with 5% aqueous HCl, saturatedNaHCO₃, brine, dried (Na₂SO₄) and concentrated under vacuum.Purification by column chromatography (SiO₂, eluting sequentially withCHCl₃; 3% acetone/CHCl₃; and finally 5% acetone/CHCl₃) gave Compound 6a(2.25 g, 55% from Compound 4) and Compound 6b (1.84 g, 45% from Compound4).

6a ¹H NMR (300 MHz, CDCl₃) δ: 7.44-7.29 (m, 5H), 5.68 (d, 1H, J=3.8),4.76 (d, 1H, J=12.0), 4.62 (d, 1H, J=12.0), 4.58 (m, 1H), 4.44 (d, 1H,J=10.3), 4.08 (d, 1H, J=5.3), 3.95 (m, 1H), 3.81 (d, 1H, J=10.3), 2.84(d, 1H, J=7.5), 1.60 (s, 3H), 1.30 (s, 3H), 1.20 (d, 3H, J=6.4), 0.88(s, 9H), 0.08 (s, 3H), 0.05 (s, 3H).

6b ¹H NMR (300 MHz, CDCl₃) δ: 7.39-2.29 (m, 5H), 5.73 (d, 1H, J=3.9),4.76 (d, 1H, J=11.7), 4.58 (m, 1H, partially overlapped), 4.56 (d, 1H,J=11.7), 4.16 (d, 1H, J=5.2), 4.14-4.04 (m, 3H), 2.43 (d, 1H, J=3.8),1.62 (s, 3H), 1.32 (s, 3H), 1.17 (d, 3H, J=6.52), 0.88 (s, 9H), 0.08 (s,3H), 0.05 (s, 3H).

D) Preparation of Compound 7a

Isobutyryl chloride (0.67 mL, 6.3 mmol) was added to a cold (0° C.)solution of Compound 6a (2.29 g, 5.3 mmol), triethylamine (1.06 mL, 7.6mmol) and 4-dimethylaminopyridine (77 mg, 0.6 mmol) in CH₂Cl₂ (6 mL).After stirring at room temperature for 16 hours, the reaction was pouredinto EtOAc and the organic layer was sequentially washed with 5% aqueousHCl, saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated undervacuum to provide Compound 7a, which was used without purification inthe next step.

E) Preparation of Compound 8a

70% HF/pyridine (1.25 mL) was added to a solution of crude Compound 7ain THF (25 mL) in a polypropylene tube. After stirring at roomtemperature for 16 hours, triethylamine (1.25 mL) was added to thereaction. After 10 minutes, the reaction was poured into EtOAc andextracted with water, brine, dried (Na₂SO₄) and filtered. Additionaltriethylamine (1.25 mL) was added to the EtOAc solution and the reactionwas concentrated under vacuum to provide Compound 8a, which was usedwithout further purification in the next step.

F) Preparation of Compound 9a

Methanesulfonyl chloride (0.46 mL, 5.8 mmol) was added to a cold (0° C.)solution of crude Compound 8a, triethylamine (1.1 mL, 7.8 mmol) and4-dimethylaminopyridine (60 mg, 0.5 mmol) in CH₂Cl₂ (21 mL). Afterstirring at room temperature for 1 hour, the reaction was poured intoCHCl₃ and the organic layer was sequentially washed with 5% aqueous HCl,saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated under vacuum togive Compound 9a, which was used without purification in the next step.

G) Preparation of Compound 10a

Concentrated H₂SO₄ (1 drop) was added to a solution of crude Compound 9ain glacial acetic acid (9 mL) and acetic anhydride (1.3 mL). Afterstirring at room temperature for 1 hour, the reaction was poured intoEtOAc and the organic layer was washed with water, saturated NaHCO₃,brine, dried (Na₂SO₄) and concentrated under vacuum. Purification bycolumn chromatography (SiO₂, eluting with 40% EtOAc/hexanes) gaveCompound 10 a (2.71 g, 99% from Compound 6a) as a colorless oil.

H) Preparation of Compound 11a

N,O-Bis(trimethylsilyl)acetamide (3.9 mL, 15.7 mmol) was added to asuspension of Compound 10a (2.7 g, 5.2 mmol) and uracil (0.73 g, 6.5mmol) in MeCN (16 mL). After heating at 40° C. for 15 minutes to get aclear solution, trimethylsilyl triflate (1.23 mL, 6.8 mmol) was added tothe reaction. After refluxing for 2 hours, the reaction was cooled toroom temperature and poured into EtOAc. The organic layer was washedwith saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated undervacuum to give Compound 11a, which was used without purification in thenext step.

I) Preparation of Compound 12a

A solution of NaOH (2M, 11 mL) was added to a solution of crude Compound11a in 1,4-dioxane:H₂O (1:1, 12 mL). After stirring at room temperaturefor 16 hours, the reaction was neutralized with 5% aqueous HCl (pH ˜7)and extracted with a mixture of 25% pyridine/EtOAc. The organic layerwas further washed with 50% brine, brine, dried (Na₂SO₄) andconcentrated under vacuum. Purification by column chromatography (SiO₂,5% MeOH/CHCl₃) gave Compound 12a as a white solid (1.56 g, 83% fromCompound 10a). ¹H NMR (300 MHz, CDCl₃) δ: 8.48 (s, br, 1H), 7.71 (d, 1H,J=8.2), 7.40-7.29 (m, 5H), 5.71 (d, 1H, J=8.3), 5.67 (s, 1H), 4.67 (d,2H, J=11.5), 4.54 (d, 1H, J=11.5), 4.48 (s, 1H), 4.19 (m, 1H), 4.03 (s,1H, J=7.8), 3.91 (s, 1H), 3.76 (d, 1H, J=7.8), 1.32 (d, 3H, J=6.6).

J) Preparation of Compound 13a

Isobutyric anhydride (0.86 mL, 5.2 mmol) was added to a cold solution(0° C.) of Compound 12a (1.56 g, 4.3 mmol) and 4-dimethylaminopyridine(10 mg) in pyridine (8.6 mL). The reaction was stirred for 16 hoursduring which it gradually warmed to room temperature. The reaction waspoured into EtOAc and extracted with brine, dried (Na₂SO₄) andconcentrated under vacuum. Purification by column chromatography (SiO₂,50% EtOAc/hexanes) gave Compound 13a (1.68 g, 90%) as a white solid.

K) Preparation of Compound 14a

MeOH (20 mL) was carefully added to a mixture of Pd/C (10% w/w, 190 mg)and Compound 13a (1.68 g, 3.9 mmol). The above mixture was hydrogenatedusing a H₂ balloon for 16 hours. The catalyst was removed by filtrationthrough celite and concentrated to provide a crude mixture of Compounds13a and 14a. The above procedure was repeated until Compound 13a couldnot be detected (TLC) in the reaction mixture. Purification by columnchromatography (SiO₂, 7% MeOH/CHCl₃) gave Compound 14a as a white solid(1.35 g, 92%).

L) Preparation of Compound 15a

tert-Butyldimethylsilyl chloride (1.95 g, 13.0 mmol) was added to asolution of Compound 14a (1.35 g, 4 mmol) and imidazole (1.76 g, 25.9mmol) in DMF (8 mL). After stirring at room temperature for 16 hours,the reaction was poured into EtOAc and extracted with brine, dried(Na₂SO₄) and concentrated under vacuum. Purification by columnchromatography (5% MeOH/CHCl₃) gave Compound 15a as a white solid (1.63g, 90%).

M) Preparation of Compound 16a

K₂CO₃ (0.99 g, 7.1 mmol) was added to a solution of Compound 16a in MeOH(20 mL). After stirring at room temperature for 16 hours, the reactionwas concentrated and purified by column chromatography (SiO₂, 10%MeOH/CHCl₃) to give Compound 16a as a white solid (1.15 g, 75%).

N) Preparation of Compound 17a

4,4′-Dimethoxytrityl chloride (DMTCl) (2.53 g, 7.5 mmol) was added to asolution of Compound 16a (1.15 g, 3.0 mmol) and 2,6-lutidine (0.87 mL,7.5 mmol) in pyridine (20 mL). The reaction was heated at 45° C. for 24hours after which additional DMTCl (0.43 g, 1.3 mmol) and 2,6-lutidine(0.15 mL, 1.27 g) was added. After heating at 45° C. for an additional24 hours, the reaction was poured into EtOAc and extracted with brine,dried (Na₂SO₄) and concentrated. Purification by column chromatography(SiO₂, 25% EtOAc/hexanes-50% EtOAc/hexanes) gave Compound 17a as ayellowish foam (2.0 g, 97%). 17a ¹H NMR (300 MHz, CDCl₃) δ: 8.75 (s, br,1H), 8.09 (d, 1H, J=8.2), 7.49-7.19 (m, 9H), 6.82 (m, 4H), 5.68 (s, 1H),5.66 (d, 1H, J=8.2, partially overlapped), 4.33 (s, 1H), 4.24 (s, 1H),3.86 (d, 1H, J=7.6), 3.80 (s, 6H), 3.72 (m, 2H), 0.96 (d, 3H, J=6.5),0.77 (s, 9H), 0.03 (s, 3H), −0.10 (s, 3H).

N) Preparation of Compound 18a

Triethylamine trihydrofluoride (1.29 mL, 8.0 mmol) was added to asolution of Compound 17a (1.09 g, 1.6 mmol) and triethylamine (0.45 mL,3.2 mmol) in THF (8 mL) in a polypropylene tube. After stirring at roomtemperature for 48 hours, the reaction was poured into EtOAc and theorganic phase was sequentially washed with H₂O, saturated NaHCO₃, brine,dried (Na₂SO₄) and concentrated under vacuum. Purification by columnchromatography (SiO₂, eluting with 25% acetone/CHCl₃-40% acetone/CHCl₃)gave Compound 18a (0.79 g, 86%) as a white foam.

O) Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylaminophosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 19a

2-cyanoethyl N,N′-tetraisopropylphosphoramidite (0.43 mL, 2.0 mmol) wasadded to a solution of Compound 18a (0.78 g, 1.4 mmol), tetrazole (76.0mg, 1.1 mmol), N-methylimidazole (28 μL, 0.3 mmol) in DMF (7 mL). Afterstirring for 8 hours at room temperature, the reaction was poured intoEtOAc and the organic phase was washed with 90% brine, brine, dried(Na₂SO₄) and concentrated under vacuum. Purification by columnchromatography (SiO2, eluting with 60% EtOAc/hexanes-75% EtOAc/hexanes)gave Compound 19a (0.91 g, 87%) as a white solid. 19a 31p NMR (300 MHz,CDCl₃) δ: 149.1, 148.5.

Example 2 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(R)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 19b (Scheme 1) A) Preparation of Compound 7b

Isobutyryl chloride (0.55 mL, 5.2 mmol) was added to a cold (0° C.)solution of Compound 6b (1.90 g, 4.4 mmol), triethylamine (0.88 mL, 6.3mmol) and 4-dimethylaminopyridine (53 mg, 0.4 mmol) in CH₂Cl₂ (5 mL).After stirring at room temperature for 16 hours, the reaction was pouredinto EtOAc and the organic layer was sequentially washed with 5% aqueousHCl, saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated undervacuum to give Compound 7b which was used without purification in thenext step.

B) Preparation of Compound 8b

70% HF/pyridine (2.0 mL) was added to a solution of crude Compound 7b inTHF (30 mL) in a polypropylene tube. After stirring at room temperaturefor 16 hours, triethylamine (2.0 mL) was added to the reaction. After 10minutes, the reaction was poured into EtOAc and extracted with water,brine, dried (Na₂SO₄) and filtered. Additional triethylamine (2.0 mL)was added to the EtOAc solution and the reaction was concentrated undervacuum to provide Compound 8b, which was used without furtherpurification in the next step.

C) Preparation of Compound 9b

Methanesulfonyl chloride (0.40 mL, 5.2 mmol) was added to a cold (0° C.)solution of crude Compound 8b, triethylamine (0.88 mL, 6.3 mmol) and4-dimethylaminopyridine (53 mg, 0.4 mmol) in CH₂Cl₂ (16 mL). Afterstirring at room temperature for 1 hour, the reaction was poured intoCHCl₃ and the organic layer was sequentially washed with 5% aqueous HCl,saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated under vacuum togive Compound 9b, which was used without purification in the next step.

D) Preparation of Compound 10b

Concentrated H₂SO₄ (1 drop) was added to a solution of crude Compound 9bin glacial acetic acid (9 mL) and acetic anhydride (1.3 mL). Afterstirring at room temperature for 1 hour, the reaction was poured intoEtOAc and the organic layer was washed with water, saturated NaHCO₃,brine, dried (Na₂SO₄) and concentrated under vacuum. Purification bycolumn chromatography (SiO₂, eluting with 40% EtOAc/hexanes) gaveCompound 10b (2.0 g, 90% from 6b) as a colorless oil.

E) Preparation of Compound 11b

N,O-Bis(trimethylsilyl)acetamide (2.73 mL, 11.0 mmol) was added to asuspension of Compound 10b (2.0 g, 3.9 mmol) and uracil (0.52 g, 4.6mmol) in CH₃CN (11 mL). After heating at 40° C. for 15 minutes to get aclear solution, trimethylsilyl triflate (0.87 mL, 4.8 mmol) was added tothe reaction. After refluxing for 2 hours the reaction was cooled toroom temperature and poured into EtOAc. The organic layer was washedwith saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated undervacuum to give crude Compound 11b, which was used without purificationin the next step.

F) Preparation of Compound 12b

A solution of NaOH (2M, 8.0 mL) was added to a solution of crudeCompound 11b in 1,4-dioxane:H₂O (1:1, 8 mL). After stirring at roomtemperature for 16 hours, the reaction was neutralized with 5% aqueousHCl (pH ˜7) and extracted with a mixture of 25% pyridine/EtOAc. Theorganic layer was further washed with 50% brine, brine, dried (Na₂SO₄)and concentrated under vacuum. Purification by column chromatography(SiO₂, 5% MeOH/CHCl₃) provided Compound 12b as a white solid (1.30 g,98% from Compound 10b). 12b ¹H NMR (300 MHz, CDCl₃) δ: 8.90 (s, br, 1H),7.52 (d, 1H, J=8.2), 7.43-7.29 (m, 5H), 5.72 (d, 1H, J=8.2), 5.64 (s,1H), 4.68 (d, 1H, J=11.5), 4.59 (s, 1H), 4.51 (d, 1H, J=11.5), 4.31 (m,1H, partially overlapped), 4.24 (d, 1H, J=8.1), 3.96 (d, 1H, J=8.1),3.79 (s, 1H), 2.25 (d, 1H, J=5.2), 1.34 (d, 3H, J=6.6).

G) Preparation of Compound 13b

Isobutyric anhydride (0.60 mL, 3.6 mmol) was added to a cold solution(0° C.) of Compound 12b (1.08 g, 3.0 mmol) and 4-dimethylaminopyridine(5 mg) in pyridine (6 mL). The reaction was stirred for 16 hours duringwhich it gradually warmed to room temperature. The reaction was pouredinto EtOAc and extracted with brine, dried (Na₂SO₄) and concentratedunder vacuum to give Compound 13b, which was used without furtherpurification in the next step.

H) Preparation of Compound 14b

MeOH (20 mL) was carefully added to a mixture of Pd/C (10% w/w, 170 mg)and Compound 13b. The above mixture was hydrogenated using a H₂ balloonfor 16 hours. The catalyst was removed by filtration through celite andconcentrated to provide a crude mixture of Compounds 13b and 14b. Theabove procedure was repeated until Compound 13b could not be detected(TLC) in the reaction mixture. Purification by column chromatography(SiO₂, 7% MeOH/CHCl₃) gave Compound 14b as a white solid (0.84 g, 83%from Compound 12b).

I) Preparation of Compound 15b

tert-Butyldimethylsilyl chloride (1.49 g, 9.9 mmol) was added to asolution of Compound 14b (0.84 g, 2.5 mmol) and imidazole (1.35 g, 19.9mmol) in DMF (5 mL). After stirring at room temperature for 16 hours,the reaction was poured into EtOAc and extracted with brine, dried(Na₂SO₄) and concentrated under vacuum. Purification by columnchromatography (5% MeOH/CHCl₃) gave Compound 15b as a white solid (0.92g, 81%).

J) Preparation of Compound 16b

K₂CO₃ (0.70 g, 5.1 mmol) was added to a solution of Compound 15b in MeOH(10 mL). After stirring at room temperature for 16 hours, the reactionwas concentrated and partitioned between 90% brine and 25%pyridine/EtOAc. The organic phase was collected, dried (Na₂SO₄) andconcentrated under vacuum to give crude Compound 16b, which was usedwithout further purification in the next step.

K) Preparation of Compound 17b

4,4′-Dimethoxytrityl chloride (DMTCl) (1.87 g, 5.5 mmol) was added to asolution of Compound 16b (0.71 g, 1.8 mmol) and 2,6-lutidine (0.64 mL,5.5 mmol) in pyridine (20 mL). After heating at 45° C. for 48 hours, thereaction was poured into EtOAc and extracted with brine, dried (Na₂SO₄)and concentrated. Purification by column chromatography (SiO₂, 25%EtOAc/hexanes-50% EtOAc/hexanes) gave Compound 17b as a yellowish foam(1.29 g, 93% from Compound 15b). 17b ¹H NMR (300 MHz, CDCl₃) δ: 8.70 (s,br, 1H), 7.61 (d, 1H, J=8.2), 7.49-7.16 (m, 9H), 6.82 (d, 4H, J=8.9),5.63 (s, 1H), 5.56 (d, 1H, J=8.2), 4.25 (s, 1H), 3.97 (d, 1H, J=8.1),3.85 (s, 1H), 3.79 (s, 6H), 3.70 (d, 1H, J=8.1), 3.58 (m, 1H), 1.12 (d,3H, J=6.6), 0.79 (s, 9H), 0.01 (s, 3H), −0.01 (3H)

L) Preparation of Compound 18b

Triethylamine trihydrofluoride (1.06 mL, 6.5 mmol) was added to asolution of Compound 17b (0.89 g, 1.3 mmol) and triethylamine (0.46 mL,3.3 mmol) in THF (6.5 mL) in a polypropylene tube. After stirring atroom temperature for 48 hours, the reaction was poured into EtOAc andthe organic phase was sequentially washed with H₂O, saturated NaHCO₃,brine, dried (Na₂SO₄) and concentrated under vacuum. Purification bycolumn chromatography (SiO₂, eluting with 30% acetone/CHCl₃-45%acetone/CHCl₃) gave Compound 18b (0.73 g, 98%) as a white foam.

M) Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(R)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 19b

2-Cyanoethyl N,N′-tetraisopropylphosphoramidite (0.60 mL, 1.9 mmol) wasadded to a solution of Compound 18b (0.73 g, 1.3 mmol), tetrazole (71mg, 1.0 mmol), N-methylimidazole (26 μL, 0.3 mmol) in DMF (6 mL). Afterstirring for 8 hours at rt, the reaction was poured into EtOAc and theorganic phase was washed with 90% brine, brine, dried (Na₂SO₄) andconcentrated under vacuum. Purification by column chromatography (SiO₂,eluting with 10% acetone/CHCl₃-15% acetone/CHCl₃) gave Compound 19b(0.89 g, 91a %) as a white solid. 19b ³¹P NMR (300 MHz, CDCl₃) δ: 149.4,148.6.

Compound 19a is prepared following the procedures illustrated forcompound 19b using compounds 6a-18a in place of 6b-18b as illustrated inthe schemes above.

Example 3 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(4-N-benzoylcytosin-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 24a

A) Preparation of Compound 20a

Phosphorus oxychloride (0.98 mL, 10.5 mmol) was added dropwise to a cold(0° C.) suspension of 1,2,4-triazole (3.10 g, 44.9 mmol) in CH₃CN (17mL). After stirring for 10 minutes, triethylamine (7.4 mL, 51.8 mmol)was added to the reaction and stirring was continued for 30 minutes. Asolution of Compound 17a (0.91 g, 1.3 mmol) in CH₃CN (8 mL) was added tothe reaction and the stirring was continued for 4 hours at roomtemperature. The reaction was poured into EtOAc and the organic layerwas washed with H₂O, saturated NaHCO₃, brine, dried (Na₂SO₄) andconcentrated to give crude Compound 20a, which was used without furtherpurification in the next step.

B) Preparation of Compound 21a

Aqueous ammonia solution (4 mL) was added to a solution of Compound 20ain 1,4-dioxane (20 mL). After stirring for 16 hours at room temperature,the reaction was concentrated under vacuum. Purification by columnchromatography (SiO₂, eluting with 5% MeOH/CHCl₃) gave Compound 21a(0.80 g, 89% from Compound 17a) as a white solid.

C) Preparation of Compound 22a

Benzoic anhydride (0.41 g, 1.8 mmol) was added to a solution of Compound21a (0.80 g, 1.2 mmol) in N,N-dimethylformamide (3 mL). After stirringfor 16 hours at room temperature, the reaction was concentrated underhigh vacuum. Purification by column chromatography (SiO₂, eluting with50% EtOAc/hexanes) gave Compound 22a (0.81 g, 88%).

D) Preparation of Compound 23a

Triethylamine trihydroflouride (1.00 mL, 6.1 mmol) was added to asolution of Compound 22a (0.81 g, 1.1 mmol) and triethylamine (0.35 mL,2.5 mmol) in THF (7 mL). After stirring at room temperature for 48hours, the reaction was poured into EtOAc and the organic layer waswashed with H₂O, saturated NaHCO₃, brine, dried (Na₂SO₄) andconcentrated. Purification by column chromatography (SiO₂, eluting with90% EtOAc/hexanes) gave Compound 23a (0.68 g, 99%).

E) Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(4-N-Benzoylcytosin-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 24a

2-cyanoethyl N,N′-tetraisopropylphosphoramidite (0.48 mL, 1.5 mmol) wasadded to a solution of Compound 23a (0.68 g, 1.0 mmol), tetrazole (56mg, 0.81 mmol), N-methylimidazole (20 μL, 0.3 mmol) in DMF (5 mL). Afterstirring for 8 hours at room temperature, the reaction was poured intoEtOAc and the organic phase was washed with 90% brine, brine, dried(Na₂SO₄) and concentrated under vacuum. Purification by columnchromatography (SiO₂, eluting with 60% EtOAc/hexanes—90% EtOAc/hexanes)gave Compound 24a (0.73 g, 84%) as a white solid. 24a ³¹P NMR (300 MHz,CDCl₃) δ: 149.4, 148.6.

Example 4 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(R)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(4-N-benzoylcytosin-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 24b (Scheme 2) A) Preparation of Compound 20b

Phosphorus oxychloride (1.3 mL, 14.0 mmol) was added dropwise to a cold(0° C.) suspension of 1,2,4-triazole (4.10 g, 59.5 mmol) in CH₃CN (30mL). After stirring for 10 minutes, triethylamine (9.80 mL, 70.0 mmol)was added to the reaction and stirring was continued for 30 minutes. Asolution of the Compound 17b (1.20 g, 1.8 mmol) in CH₃CN (10 mL) wasadded to the reaction and the stirring was continued for 4 hours at roomtemperature. The reaction was poured into EtOAc and the organic layerwas washed with H₂O, saturated NaHCO₃, brine, dried (Na₂SO₄) andconcentrated to give crude Compound 20b, which was used without furtherpurification in the next step.

B) Preparation of Compound 21b

Aqueous ammonia solution (5 mL) was added to a solution of triazolide20b (from above) in 1,4-dioxane (25 mL). After stirring for 16 hours atroom temperature, the reaction was concentrated to provide Compound 21bwhich was dried under high vacuum for 24 hours and used without furtherpurification in the next step.

C) Preparation of Compound 22b

Benzoic anhydride (0.59 g, 2.6 mmol) was added to a solution of Compound21b (0.80 g, 1.2 mmol) in N,N-dimethylformamide (3 mL). After stirringfor 16 hours at room temperature, the reaction was concentrated underhigh vacuum. Purification by column chromatography (SiO₂, eluting with50% EtOAc/hexanes) gave Compound 22b (1.36 g, 87% from Compound 17b).

D) Preparation of Compound 23b

Triethylamine trihydroflouride (1.66 mL, 10.2 mmol) was added to asolution of Compound 23b (1.35 g, 1.7 mmol) and triethylamine (0.57 mL,4.1 mmol) in THF (12 mL). After stirring at room temperature for 48hours, the reaction was poured into EtOAc and the organic layer waswashed with H₂O, saturated NaHCO₃, brine, dried (Na₂SO₄) andconcentrated. Purification by column chromatography (SiO₂, eluting with20% to 40% acetone in chloroform) gave Compound 23b (1.03 g, 90%).

E) Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)-phosphinoxy]-1-[1-(R)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(4-N-benzoylcytosin-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 24b

2-Cyanoethyl N,N′-tetraisopropylphosphoramidite (0.73 mL, 2.3 mmol) wasadded to a solution of Compound 23b (1.03 g, 1.53 mmol), tetrazole (85mg, 1.2 mmol), N-methylimidazole (31 μL, 0.38 mmol) in DMF (7.7 mL).After stirring for 8 hours at room temperature, the reaction was pouredinto EtOAc and the organic phase was washed with 90% brine, brine, dried(Na₂SO₄) and concentrated under vacuum. Purification by columnchromatography (SiO₂, eluting with 60% to 90% EtOAc/hexanes) gaveCompound 24b (1.22 g, 91%) as a white solid. 24b ³¹P NMR (300 MHz,CDCl₃) δ: 149.5, 148.8.

Example 5 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(6-N-benzoyladenin-9-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 33a

Compound 25a is prepared by the Vorbruggen reaction of Compound 10ausing 6-N-Bz-Adenine, BSA and TMSOTf in refluxing dichloroethane.Subsequent reaction of 25a with sodium hydroxide in dioxane/water,followed by reprotection of the 4-amino group with benzoyl chlorideprovides nucleoside Compound 26a. The phosphoramidite, Compound 33a isprepared from nucleoside Compound 26a following the same steps asillustrated for Compound 19a from Compound 11a.

Example 6 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(R)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(6-N-benzoyladenin-9-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 33b (Scheme 3)

Compound 25b is prepared by the Vorbruggen reaction of Compound 10busing 6-N-Bz-Adenine, BSA and TMSOTf in refluxing dichloroethane.Subsequent reaction of 25b with sodium hydroxide in dioxane/water,followed by reprotection of the 4-amino group with benzoyl chlorideprovides nucleoside Compound 26b. The phosphoramidite, Compound 33b isprepared from nucleoside Compound 26b following the same steps asillustrated for Compound 19b from Compound 11b.

Example 7 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(2-N-isobutyrylguanin-9-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 42a

Compound 34a is prepared by the Vorbruggen reaction of Compound 10ausing 2-amino-6-chloropurine, BSA and TMSOTf in refluxingdichloroethane. Reaction of nucleoside 34a with 3-hydroxypropionitrileand sodium hydride provides the cyclized nucleoside 35a. Thephosphoramidite, Compound 42a is prepared from nucleoside Compound 35afollowing the same steps as illustrated for Compound 19a from Compound11a.

Example 8 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(R)-(4,4′-dimethoxytrityl)oxy-ethyl]-3-(2-N-isobutyrylguanin-9-yl)-2,5-dioxa-bicyclo[2.2.1]heptane,Compound 42b (Scheme 4)

Compound 34b is prepared by the Vorbruggen reaction of Compound 10busing 2-amino-6-chloropurine, BSA and TMSOTf in refluxingdichloroethane. Reaction of nucleoside 34b with 3-hydroxypropionitrileand sodium hydride provides the cyclized nucleoside 35b. Thephosphoramidite, Compound 42b is prepared from nucleoside Compound 35bfollowing the same steps as illustrated for Compound 19b from Compound11b.

Example 9 Preparation of Compound 48

A) Preparation of Compound 44

Commercially available 1,2;5,6-di-O-isopropylidene-α-D-allofuranose,Compound 43, (135 g, 519.0 mmol) and 2-(bromomethyl)-naphthalene (126 g,570.0 mmol) were dissolved in DMF (500 mL) in a three-necked flask (500mL) and the reaction was cooled in an ice bath. Sodium hydride (60% w/w,29 g, 727.0 mmol) was carefully added (6 g portions every 10 minutes) tothe reaction and the stirring was continued for another 60 minutes afterthe addition was complete. At this time TLC analysis showed no morestarting sugar 43. The reaction was carefully poured onto crushed ice(ca. 500 g) and the resulting slurry was stirred vigorously until allthe ice melted. The resulting off-white solid was collected byfiltration and suspended in water. The suspension was stirred vigorouslyusing a mechanical stirrer for 30 minutes after which the solid wascollected by filtration and suspended in hexanes. The suspension wasstirred vigorously for 30 minutes after which the solid was collected byfiltration and air dried for 4-6 hours and then dried under high vacuumover P₂O₅ for 16 hours to provide Compound 44 (206.0 g, 99%) as anoff-white solid. ¹H NMR (300 MHz, CDCl₃) δ: 7.85 (m, 4H), 7.48 (m, 3H),5.74 (s, 1H), 4.92 (d, 1H, J=11.7), 4.75 (d, 1H, J=11.6), 4.58 (m, 1H),4.36 (m, 1H), 4.15 (m, 1H), 4.03-3.86 (m, 3H), 1.61 (s, 3H), 1.36 (s,9H).

B) Preparation of Compound 45

Compound 44 (200.0 g, 0.5 moles) was added in small portions to asolution of acetic acid (2.2 L) and water (740 mL). The reaction wasstirred at room temperature for 16 h after which, TLC analysis (30%EtOAc/hexanes) indicated complete consumption of 44. The reaction wasthen concentrated under reduced pressure until most of the acetic acidwas removed. The remaining solution was poured into a stirred mixture ofEtOAc (1 L) and water (1 L). Solid KOH was then added to the abovemixture until the aqueous layer was strongly basic (pH>12). The organiclayer was then separated, washed with saturated sodium bicarbonatesolution, brine, dried (Na₂SO₄), filtered and concentrated under reducedpressure to provide Compound 45 as a yellow foam, which was used withoutany further purification.

C) Preparation of Compound 46

A solution of NaIO₄ (107.0 g) in water (3 L) was added over 40 minutesto a stirred (mechanical stirrer) solution of Compound 45 (crude fromabove) in dioxane (1.5 L) After 60 minutes the reaction mixture waspoured into EtOAc (1.5 L) and the organic layer was separated, washedwith water (1 L), brine (1 L), dried (Na₂SO₄) and concentrated toprovide Compound 46 as a yellow oil, which was used without any furtherpurification.

D) Preparation of Compound 47

Compound 46 (crude from above) was dissolved in a mixture of THF (500)and water (500 mL) and the reaction was cooled in an ice bath. 2N NaOH(600 mL) and formaldehyde (250 mL of a 37% aqueous solution) were addedto the reaction and the stirring was continued at room temperature for 3days. The reaction was then poured into EtOAc (1 L) and washed withwater (1 L), brine (1 L) and evaporated under reduced pressure untilapproximately 200 mL of EtOAc was left (a white precipitate was formedin the process). Hexanes (300 mL) was added to the precipitate and themixture was allowed to stand for 16 hours after which the white solidwas collected by filtration, washed with hexanes and dried under highvacuum over P₂O₅ to provide Compound 47 as a white solid (124 g, 66%from 44). ¹H NMR (300 MHz, CDCl₃) δ: 7.85 (m, 4H), 7.48 (m, 3H), 5.75(d, 1H, J=3.9), 4.96 (d, 1H. J=11.8), 4.75 (d, 1H, J=11.8), 4.66 (m,1H), 4.26 (d, 1H, J=5.2), 3.95 (m, 2H), 3.79 (m, 1H), 3.63 (m, 1H), 2.39(m, 1H, OH), 1.66 (s, 3H), 1.34 (s, 3H).

E) Preparation of Compounds 48 and 49

tert-Butyldiphenylchlorosilane (305.0 mmol, 84.0 mL) was added to a cold(0° C.) stirring solution of Compound 47 (278.0 mmol, 100.0 g) andtriethylamine (305 mmol, 43.0 mL) in dichloromethane (600 mL). After theaddition was complete, the reaction was warmed to room temperature andthe stirring was continued for 16 hours. MeOH (50 mL) was added (toquench the excess TBDPSCl) to the reaction and the stirring wascontinued for another 2 hours at room temperature. The reaction was thendiluted with chloroform and the organic layer was washed with 10% HCl,saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated to provide athick oil. Hexanes (150 mL) was added to the oil and the mixture wassonicated until a solution resulted. The solution was now seeded with asmall amount of 6 (previously isolated by column chromatography). Afterstanding for 16 hours additional hexanes was added to the thick slurryand the solid was collected by filtration. The solid was thenresuspended in hexanes and stirred vigorously for 30 minutes. The solidwas collected by filtration to provide 6 (80.5, 48% g) after dryingunder high vacuum for 16 hours. The filtrates were combined andconcentrated under reduced pressure. The resulting oil was redissolvedin minimum amount of hexanes and passed through a plug of silica gel(eluting with 20% EtOAc in hexanes). Fractions containing the product 6were combined, concentrated and crystallized as described above toprovide a second crop of 6 (20 g, 12%) as a white solid. Further elutionof the silica gel plug with 50% EtOAc in hexanes provided pure Compound48 (40.0 g, 24%) as a thick oil. In addition a mixture of 48 and 49 (ca15 g, 9%) was also isolated as a thick oil. Diol 48; ¹H NMR (300 MHz,CDCl₃) δ: 7.83 (m, 4H), 7.56 (m, 7H), 7.30 (m, 6H), 5.80 (s, 1H), 4.97(d, 1H, J=11.4), 4.70 (m, 2H), 4.46 (m, 1H), 3.92-3.66 (m, 4H), 2.39 (m,1H, OH), 1.67 (s, 3H), 1.37 (s, 3H), 0.92 (s, 9H). Diol 7; ¹H NMR (300MHz, CDCl₃) δ: 7.9-7.3 (m, 17H), 5.71 (d, 1H, J=3.9), 4.86 (d, 1H,J=12.2), 4.74 (d, 1H, J=12.2), 4.56 (m, 1H), 4.22 (d, 1H, J=11.1), 4.18(m, 1H), 4.07 (d, 1H, J=11.1), 4.02 (dd, 1H, J=4.2, 12.0), 3.64 (dd, 1H,J=9.4, 11.9), 1.89 (m, 1H), 1.25 (s, 6H), 1.05 (s, 9H).

F) Recover Compound 47 from Compound 49

Tetrabutylammonium fluoride (70 mL of a 1 M solution in THF) was addedto a cold (0° C.) stirring solution of diol 49 (62.7 mmol, 37.5 g) inTHF (250 mL) after which, the reaction was allowed to warm to roomtemperature gradually. After stirring for an additional 72 hours, thereaction was concentrated under vacuum and the residue was poured ontocrushed ice. The flask was rinsed with some additional THF (3 times) andadded to the above suspension. The supernatant was removed bydecantation and the solid at the bottom was added to a stirring mixtureof hexanes (200 mL) and water (200 mL). After stirring for 2 hours, theflocculent solid was collected by filtration, washed with additionalwater and hexanes and dried under high vacuum to provide Compound 47 (20g, 89%) as a white solid.

Example 10 Preparation of Compound 60

A) Preparation of Compound 51

Pivaloyl chloride (25 mmol, 3.0 mL) was added dropwise to a cold (0° C.)solution of Compound 48 (16.7 mmol, 10.0 g), diisopropylethylamine (25.0mmol, 4.4 mL) and dimethylaminomethylpyridine (2.5 mmol, 0.30 g) indichloromethane (35 mL). After stirring at room temperature for 16hours, the reaction was diluted with chloroform and the organic layerwas washed with 5% HCl, saturated NaHCO₃, brine, dried (Na₂SO₄) andconcentrated to provide crude Compound 51, which was used without anyfurther purification.

B) Preparation of Compound 52

70% HF/pyridine (4.2 mL) was added to a cold (0° C.) solution of crude51 (from above). After stirring for 16 hours at room temperature,additional 70% HF/pyridine (2.5 mL) was added to the reaction. Afterstirring another 2 days at room temperature, triethylamine (7.5 mL) wascarefully added to the reaction. After stirring for 1 hour, the reactionwas carefully quenched with saturated NaHCO₃ until pH>10. The reactionwas diluted with EtOAc and the organic layer was further washed withbrine, dried (Na₂SO₄) and concentrated. Purification by columnchromatography (SiO₂, eluting with 25 to 40% EtOAc in hexanes) providedCompound 52 (7.01 g, 95% from Compound 48) as an oil.

C) Preparation of Compound 53

DMSO (3.30 mL, 46.7 mmol) was added to a cold (−78° C.) solution ofoxalyl chloride (23.3 mmol, 2.0 mL) in dichloromethane (120 mL). Afterstirring for 30 minutes, Compound 52 (15.6 mmol, 6.91 g) indichloromethane (30 mL) was added to the reaction via a cannula. Afterstirring for 45 minutes at −78° C., triethylamine (70.0 mmol, 9.60 mL)was added and the reaction was allowed to warm up to 0° C. TLC analysisat this time indicated no starting material, Compound 52, so thereaction was diluted with chloroform and the organic layer was washedwith 10% HCl, saturated NaHCO₃, brine, dried (Na₂SO₄) and concentratedto provide Compound 53, which was used without any further purification.

D) Preparation of Compounds 54 and 55

Vinyl magnesium bromide (1 M in THF, 31.1 mL) was slowly added to a cold(−78° C.) solution of Compound 53 in THF (120 mL). After stirring at−78° C. for 2 hours, the reaction was quenched with saturated NH₄Cl andthe reaction was diluted with EtOAc. The organic layer was washed with10% HCl, saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated toprovide Compound 54 and Compound 55 as a mixture, which was used withoutany further purification.

E) Preparation of Compounds 56 and 57

A solution of NaOH (4M, 12.5 mL) was added to a solution of Compounds 54and Compound 55 in dioxane/methanol (30 mL/10 mL). After stirring for 4hours at room temperature, the solvents were evaporated under reducedpressure and the residue was dissolved in EtOAc. The organic layer waswashed with water, brine, dried (Na₂SO₄) and concentrated. Purificationby column chromatography (SiO₂, eluting with 33 to 40% EtOAc in hexanes)provided Compound 57 (2.42 g, 40% from 53) as an oil. Increasingpolarity (60% EtOAc in hexanes) of the eluant provided Compound 56 (0.82g, 14% from Compound 53). 57 ¹H NMR (300 MHz, CDCl₃) δ: 7.94-7.73 (m,4H), 7.60-7.46 (m, 3H), 6.04-5.85 (m, 1H), 5.69 (d, 1H, J=3.6), 5.36 (d,1H, J=17.3), 5.24 (d, 1H, J=10.6), 4.97 (d, 1H, J=11.7), 4.74 (d, 1H,J=11.7), 4.59 (m, 1H), 4.33 (m, 2H), 4.19 (d, 1H, J=11.9), 3.85 (d, 1H,J=11.9), 1.65 (s, 3H), 1.34 (s, 3H).

F) Preparation of Compound 58

Tosyl chloride (9.3 mmol, 1.77 g) was added to a cold (0° C.) solutionof Compound 57 (2.43 g, 6.29 mmol) in pyridine (12.6 mL). After stirringat 0° C. for 8 hours, the reaction was quenched with water and dilutedwith EtOAc. The organic layer was washed with 5% HCl, saturated NaHCO₃,brine, dried (Na₂SO₄) and concentrated. Purification by columnchromatography (SiO₂, eluting with 15 to 25% EtOAc in hexanes) providedCompound 58 (2.58 g, 76%) as a white solid. Unreacted 57 (0.0.39 g, 16%)was also isolated.

G) Preparation of Compound 59

Isobutyryl chloride (6.9 mmol, 0.73 mL) was added to a cold (0° C.)solution of Compound 58 (4.6 mmol, 2.48 g), diisopropylethylamine (6.9mmol, 0.88 mL) and dimethylaminomethylpyridine (0.68 g, 83 mg) indichloromethane (9 mL). After 2 hours at 0° C., additional isobutyrylchloride (6.9 mmol, 0.73 mL) and diisopropylethylamine (6.9 mmol, 0.88mL) were added to the reaction. After another 2 hours at 0° C.,additional isobutyryl chloride (6.9 mmol, 0.73 mL) anddiisopropylethylamine (6.9 mmol, 0.88 mL) were added to the reaction andthe reaction was stirred at 0° C. for 16 hours. Water was carefullyadded to the reaction to quench any unreacted acid chloride and thestirring was continued for 1 hour at room temperature. The reaction wasthen diluted with chloroform and the organic layer was washed with 5%HCl, saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated.Purification by column chromatography (SiO₂, eluting with 25% EtOAc inhexanes) provided Compound 59 (2.2 g, 83%) as an oil. Unreacted 58 (0.31g, 13%) was also isolated after purification.

H) Preparation of Compound 60

Concentrated sulfuric acid (3-4 drops) was added to a solution ofCompound 59 (3.6 mmol, 2.20 g) in acetic acid (11 mL) and aceticanhydride (3 mL). After stirring for 2 hours at room temperature, thesolvents were removed under high vacuum on a rotary evaporator (no heat)and the residue was dissolved in EtOAc. The organic layer was carefullywashed with saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated toprovide Compound 60, which was dried under high vacuum over P₂O₅ andused without any further purification. 60 LCMS: M+23 calcd. 677.2, found677.1; LC retention time 2.05 min.

Example 11 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-(3-propenyl)]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane(69)

A) Preparation of Compound 61

N,O-bis-trimethylsilylamide (18.0 mmol, 4.4 mL) was added to asuspension of Compound 60 (3.6 mmol, crude from above) and uracil (7.2mmol, 0.81 g) in acetonitrile (18 mL) and the suspension was gentlyheated (using a heat gun) until a solution resulted. The reaction wascooled in an ice bath and TMSOTf (7.2 mmol, 1.3 mL) was added to thereaction. After the addition was complete, the ice bath was removed andthe reaction was refluxed for 2 hours after which it was cooled to roomtemperature, diluted with EtOAc and carefully quenched with saturatedNaHCO₃ solution. The organic layer was further washed with brine, dried(Na₂SO₄) and concentrated to provide crude Compound 61, which was usedwithout any further purification.

B) Preparation of Compound 62

A solution of NaOH (2M, 7.2 mL) was added to a cold (0° C.) solution ofcrude Compound 61 (from above) in dioxane (10 mL). After 2 hours at 0°C., an additional amount of NaOH (2M, 10 mL) was added to the reaction.After stirring for 16 hours at room temperature, the reaction wasacidified with 5% HCl (pH 4-5), diluted with EtOAc and the organic layerwas washed with water, brine, dried (Na₂SO₄) and concentrated. A whiteprecipitate was formed, which was carefully washed with ether and driedover high vacuum to provide nucleoside Compound 62 (0.97 g, 64%).Purification of the ether washes by column chromatography (SiO₂, elutingwith 25% acetone in chloroform) provided an additional amount ofpartially pure Compound 62 (0.10 g, 7%).

C) Preparation of Compound 63

Benzoic anhydride (2.8 mmol, 0.64 g) was added to a solution of Compound62 (2.0 mmol, 0.85 g) in pyridine (4 mL). After stirring at roomtemperature for 6 hours, the reaction was quenched with water anddiluted with EtOAc. The organic layer was washed with saturated NaHCO₃,brine, dried (Na₂SO₄) and concentrated. Purification by columnchromatography (SiO₂, eluting with 50% EtOAc in hexanes) providedCompound 63 (1.069 g, quantitative) as a white solid.

D) Preparation of Compound 64

DDQ (3.8 mmol, 0.86 g) was added to a solution of Compound 64 (1.9 mmol,1.0 g) in dichloromethane (19 mL) and water (1 mL). After stirring atroom temperature for 24 hours, the reaction was concentrated underreduced pressure. The residue was dissolved in EtOAc and the organiclayer was washed with water, 10% sodium bisulfite, saturated NaHCO₃,brine, dried (Na₂SO₄) and concentrated. Purification by columnchromatography (SiO₂, eluting with 75% EtOAc in hexanes) providedCompound 64 (0.74 g, quantitative).

E) Preparation of Compound 65

TBSCl (5.8 mmol, 0.87 g) was added to a solution of Compound 64 (1.9mmol, 0.75 g) and imidazole (11.6 mmol, 0.79 g) in DMF (5 mL). Afterstirring at room temperature for 16 hours, the reaction was diluted withEtOAc and the organic layer was washed with water, brine, dried (Na₂SO₄)and concentrated. Purification by column chromatography (SiO₂, 50% EtOAcin hexanes) provided Compound 65 (0.89 g, 94%) as a white foam.

F) Preparation of Compound 66

Compound 65 (1.6 mmol, 0.8 mmol) was dissolved in a solution of ammoniain methanol (7M, 25 mL). After heating in a sealed vessel at 45° C. for4 days, the solvent was removed under reduced pressure. Purification bychromatography (SiO₂, 2 to 4% methanol in chloroform) provided compound66 (0.65 g, quantitative) as a white solid. 66 ¹H NMR (300 MHz, CDCl₃)δ: 8.57 (s, br, 1H), 7.84 (d, 1H, J=8.2), 6.10-5.96 (m, 1H), 5.74 (d,1H, J=8.2), 5.64 (s, 1H), 5.41-5.44 (m, 2H), 4.35 (m, 1H), 4.26 (s, 1H),4.13 (s, 1H), 3.95 (d, 1H, J=7.8), 3.66 (d, 1H, J=7.8), 2.04 (d, 1H,J=4.3), 0.90 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H).

G) Preparation of Compound 67

A solution of compound 66 (0.25 mmol, 0.1 g), DMTCl (0.63 mmol, 0.21 g)and 2,6-lutidine (0.63 mmol, 73 μL) in pyridine (1.25 mL) was heated at45° C. for 10 days. The reaction was cooled to room temperature anddiluted with EtOAc. The organic layer was washed with saturated sodiumbicarbonate, brine, dried (Na₂SO₄) and concentrated under reducedpressure. Purification by column chromatography (SiO₂, eluting with 15to 45% EtOAc in hexanes) provided compound 67 (0.16 g, 93%) as a whitesolid. 67 ¹H NMR (300 MHz, CDCl₃) δ: 8.92 (s, br, 1H), 8.26 (d, 1H,J=8.2), 7.53-7.24 (m, 9H), 6.97-6.78 (m, 4H), 6.08-5.88 (m, 1H), 5.73(s, 1H), 5.68 (d, 1H, J=8.2), 4.83 (s, 1H, J=11.0), 4.58 (d, 1H,J=17.3), 4.37 (s, 1H), 4.04 (d, 1H, J=9.5), 3.84 (s, 6H, 3.78, m, 1H,partially overlapped), 3.55 (d, 1H, J=7.9), 0.83 (s, 9H), 0.11 (s, 3H),0.00 (s, 3H).

H) Preparation of Compound 68

Triethylamine trihydroflouride (1.3 mmol, 0.21 mL) was added to asolution of compound 67 (0.22 mmol, 0.15 g) and triethylamine (0.54mmol, 75 μL) in THF (2 mL). After stirring at room temperature for 2days, the reaction was diluted with EtOAc and the organic layer waswashed with saturated NaHCO₃, brine, dried (Na₂SO₄) and concentrated.LCMS: M+23 calcd. 607.2, found 607.2; LC retention time 3.51 min

I) Preparation of Compound 69

Phosphoramidite compound 69 is prepared from compound 68 according tothe procedure described for the preparation of phosphoramidite 19a fromcompound 18a in example 1.

Example 12 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-(3-propenyl)]-3-(4-N-benzoylcytosin-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane(73)

Phosphoramidite 73 is prepared from Compound 67 using the same generalprocedures described in example 3 for the preparation of phosphoramidite24a from Compound 17a.

Example 13 Alternate Route for the Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)-phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-(3-propenyl)]-3-(4-N-benzoylcytosin-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane(73)

Compound 73 is prepared using the same general procedures described forthe preparation of phosphoramidite Compound 69 from Compound 60 inexample 11. Vorbruggen reaction of Compound 60 with N-benzoyl-cytosine,BSA and TMSOTf in refluxing acetonitrile provides nucleoside Compound74. Treatment of 74 with aqueous NaOH solution effects cyclization toCompound 75. Protection of the 5′-hydroxyl group and the exocyclic aminewith BzCl in pyridine provides Compound 76. Further processing ofCompound 76 to phosphoramidite Compound 71 is similar to the proceduresdescribed for the preparation of phosphoramidite Compound 69 fromCompound 63.

Example 14 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-(3-propenyl)]-3-(6-N-benzoyladenin-9-yl)-2,5-dioxa-bicyclo[2.2.1]heptane(88)

Compound 88 is prepared using the same general procedures described forthe preparation of phosphoramidite Compound 69 from Compound 60 inexample 11. Vorbruggen reaction of Compound 60 with N-benzoyl-adenine,BSA and TMSOTf in refluxing dichloroethane provides nucleoside Compound80. Treatment of 80 with aqueous NaOH solution effects cyclization toCompound 81. Protection of the 5′-hydroxyl group and the exocyclic aminewith BzCl in pyridine provides Compound 82. Further processing ofCompound 82 to phosphoramidite Compound 88 is similar to the proceduresdescribed for the preparation of phosphoramidite Compound 69 fromCompound 63.

Example 15 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-(3-propenyl)]-3-(2-N-isobutyrylguanin-9-yl)-2,5-dioxa-bicyclo[2.2.1]heptane(97)

Compound 97 is prepared using the same general procedures described forthe preparation of phosphoramidite Compound 69 from Compound 60 inexample 11. Vorbruggen reaction of Compound 60 with2-amino-6-chloropurine, BSA and TMSOTf in refluxing dichloroethaneprovides nucleoside Compound 89. Treatment of Compound 89 with3-hydroxypropionitrile and sodium hydride effects cyclization toCompound 90. Transient protection of the 5′hydroxyl group as thetrimethylsilyl ether is followed by protection of the exocyclic aminogroup with isobutyryl chloride. Deprotection of the trimethyl silylether during aqueous workup conditions, followed by protection of the5′hydroxyl group as the benzoate ester (benzoyl chloride, pyridine)provides Compound 91. Further processing of Compound 91 tophosphoramidite Compound 97 is similar to the procedures described forthe preparation of phosphoramidite Compound 69 from Compound 63.

Example 16 Preparation of(1R,3R,4R,7S)-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4′-dimethoxytrityl)oxy-(3-propyl)]-3-(selectedbase, optionally protected)-2,5-dioxa-bicyclo[2.2.1]heptane (110-113)

A) Preparation of Compound 98

A mixture of Palladium on activated carbon (5 mg) and compound 66 (0.25mmol, 0.10 g) in MeOH (2 mL) was hydrogenated using a hydrogen balloon.After 1 hour, the reaction was filtered through celite and the filterbed was washed with EtOAc. The solvents were evaporated under reducedpressure to provide 98, which was further dried under high vacuum andused without any purification.

B) Preparation of Compound 102

A solution of compound 98 (0.25 mmol, 0.1 g), DMTCl (0.63 mmol, 0.21 g)and 2,6-lutidine (0.63 mmol, 73 μL) in pyridine (1.25 mL) was heated at45° C. for 7 days. The reaction was cooled to room temperature anddiluted with EtOAc. The organic layer was washed with saturated sodiumbicarbonate, brine, dried (Na₂SO₄) and concentrated under reducedpressure. Purification by column chromatography (SiO₂, eluting with 15to 45% EtOAc in hexanes) provided compound 102 (0.10 g, 58%) as a whitesolid. 102 (¹H NMR (300 MHz, CDCl₃) δ: 9.1 (s, br, 1H), 8.26 (d, 1H,J=8.2), 7.42-7.20 (m, 9H), 6.84-6.78 (m, 4H), 5.69 (s, 1H), 5.66 (d, 1H,overlapped), 4.33 (s, 1H), 4.32 (s, 1H), 3.85 (d, 1H, J=7.5), 3.8 (s,6H), 3.75 (d, 1H, J=7.5), 3.42 (d, 1H, J=8.2), 1.65 (m, 1H), 1.47 (m,1H), 0.79 (s, 9H), 0.25 (t, 3H, J=7.5), 0.02 (s, 3H), −0.18 (s, 3H).

C) Preparation of Compound 110

Phosphoramidite compound 110 is prepared from compound 102 using thesame general procedure described for the preparation of phosphoramiditecompound 19a from compound 17a in example 1. Phosphoramidite CompoundsIII-113 are prepared from nucleoside Compounds 79, 85 and 94.Hydrogenation of the double bond using catalytic Palladium on carbon andhydrogen provides Compounds 98-101 respectively. Protection of the 5′hydroxyl group as the dimethoxytrityl ether followed by removal of thesilyl protecting group and a phosphitylation reaction (as described inexample 1) provides phosphoramidite Compounds 110-113.

Example 17 Preparation of Compounds 116a, 116b, 116c and 116d

A) Preparation of Compound 114a

Sodium hydride (60%, 1.0 mmol, 40 mg) was added to a cold (0° C.)solution of Compound 66 (0.25 mmol, 0.10 g) and benzyloxymethyl chloride(BomCl, 0.75 mmol, 0.1 mL) in DMF (1 mL). After 1 hour, the reaction wasquenched with water and diluted with EtOAc. The organic layer was thenwashed with water, brine, dried (Na₂SO₄) and concentrated. Purificationof the residue by chromatography (SiO₂, 30% EtOAc in hexanes) providedCompound 114a (0.15 g, 93%) as a white solid.

B) Preparation of Compound 115a

A solution of osmium tetroxide (2.5% in isopropanol, 0.12 mL) was addedto a mixture of Compound 114a (0.17 g, 0.11 g), sodium periodate (0.70mmol, 0.15 g) and 2-6-lutidine (0.12 mL) in dioxane (2 mL) and water(0.5 mL). After stirring at room temperature for 36 h, the reaction wasdiluted with EtOAC and washed with water, 10% sodium thiosulfate, brine,dried (Na₂SO₄) and concentrated to provide crude Compound 115a, whichwas used without any further purification.

C) Preparation of Compound 116a

Sodium borohydride (25 mg) was added to a solution of crude Compound115a (from above) in MeOH (1 mL). After stirring at room temperature for1 hour, the reaction was diluted with EtOAc and the organic layer waswashed with 10% HCl, saturated sodium bicarbonate, brine, dried (Na₂SO₄)and concentrated. Purification of the residue by chromatography (SiO₂,eluting with 50% EtOAc in hexanes) provided Compound 116a (73 mg, 65%from 115a) as an oil. 116a (¹H NMR (300 MHz, CDCl₃) δ: 7.69 (d, 1H,J=8.2), 7.49-7.24 (m, 10H), 5.77 (d, 1H, J=8.2), 5.61 (s, 1H), 5.47 (m,2H), 4.98 (d, 1H, J=6.9), 4.84 (d, 1H, J=6.9), 4.80 (d, 1H, J=11.8),4.69 (s, 2H), 4.66 (d, 1H, J=11.8), 4.29 (s, 1H), 4.03 (s, 1H),3.96-3.79 (m, 3H), 3.67 (m, 1H), 3.22 (m, 1H), 0.87 (s, 9H), 0.07 (s,3H), 0.04 (s, 3H).

D) Preparation of Compounds 116b-d

Reaction of Compounds 79, 85 and 94 with benzyloxymethyl chloride andsodium hydride provides nucleoside Compounds 114b-d respectively.Cleavage of the double bond with osmium tetroxide provides aldehydesCompounds 115b-d. Further reduction of the aldehyde functional groupusing sodium borohydride provides Compounds 116b-d respectively.

Example 18 Preparation of Nucleosides 117a-d to 128a-d

A) Preparation of Compound 127a (R=Me)

Sodium hydride (60%, 0.23 mmol, 9 mg) was added to a cold (0° C.)solution of Compound 116a (0.11 mmol, 73 mg), iodomethane (0.57 mmol, 40μL) in DMF (0.25 mL). After stirring at 0° C. for 1 hour, the reactionwas quenched with water and diluted with EtOAC. The organic layer wasfurther washed with brine, dried (Na₂SO₄) and concentrated. Purificationby chromatography (SiO₂, eluting with 20 to 40% EtOAc in hexanes)provided compound 127a (27 mg, 37%) as an oil. 127a (¹H NMR (300 MHz,CDCl₃) δ: 7.79 (d, 1H, J=8.2), 7.45-7.28 (m, 10H), 5.74 (d, 1H, J=8.2),5.62 (s, 1H), 5.48 (m, 2H), 4.90 (m, 2H), 4.74 (d, 1H, J=11.9), 4.69 (s,1H), 4.60 (s, 1H, J=11.9), 4.29 (s, 1H), 4.04 (s, 1H), 4.04 (m, 1H,overlapped), 3.99 (d, 1H, J=8.3), 3.84 (d, 1H, J=8.2), 3.72-3.48 (m,2H), 3.35 (s, 3H), 0.87 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H).

B) Preparation of Compounds 117a-d through 123a-d

Compounds 117a-d are prepared from Compounds 116a-d by treatment with afluorinating agent such as DAST using dichloromethane as the solvent.Compounds 118a-d are prepared from Compounds 116a-d by first oxidizingthe primary hydroxyl group with Dess-Martin periodinane or under Swernconditions followed by treatment of the resulting aldehyde with DAST.Compounds 119a-d are prepared from Compounds 116a-d by first oxidizingthe primary hydroxyl group with Dess-Martin periodinane or under Swernconditions followed by reductive amination of the resulting aldehydewith a primary or a secondary amine in the presence of glacial aceticacid and a reducing agent such as sodium cyanoborohydride. Compounds120a-d are prepared from Compounds 116a-d by converting the hydroxylgroup to a thiocarbonate derivative followed by a radical deoxygenationprocedure using nBu₃SnH. Compounds 121a-d are prepared from Compounds116a-d by converting the hydroxyl group to a leaving group (mesylate,tosylate, halide) followed by heating with excess sodium azide.Compounds 124a-d are prepared from Compounds 116a-d by oxidation of theprimary alcohol to a carboxylic acid followed by reaction with a aminein the presence of HATU or any other peptide coupling reagent. Compounds125a-b are prepared from Compounds 116a-d by activating the hydroxylgroup with carbonyl diimidazole followed by reaction with a amine.Compounds 126a-d are prepared from Compounds 116a-d by oxidizing theprimary alcohol under Swern or Dess-Martin conditions followed byreaction with a suitable organometallic reagent. Compounds 127b-d (127aprepared in section A, R═CH₃ above) are prepared from Compounds 116b-dby deprotonating the hydroxyl group with an appropriate base followed byquenching the anion with an alkylating reagent. Compounds 128a-d areprepared from Compounds 116a-d by converting the hydroxyl group to aleaving group followed by displacement with a thiol nucleophile.Compounds 122a-d are prepared from Compounds 121a-d by reduction of theazide group followed by reaction with an isocyanate or anisothiocyanate. Compounds 123a-d are prepared from Compounds 121a-d byreduction of the azido group and reaction with FmocNCS to provide anactivated thiourea. Further reaction of the fmoc activated thiourea withan amine in the presence of EDC provides the substituted guanidine.Removal of the fmoc protecting group liberates Compounds 123a-d.

Example 19 Preparation of Phosphoramidites 141-144

A) Preparation of Compound 129 (Z=CH₂OMe)

A mixture of Palladium on activated carbon (3 mg) and compound 127a(0.04 mmol, 27 mg) in MeOH (1 mL) was hydrogenated using a hydrogenballoon. After 24 hours, the reaction was filtered through celite andthe filter bed was washed with EtOAc. The solvents were evaporated underreduced pressure and the residue was redissolved in MeOH (1 mL) andtriethylamine (2 drops). After stirring at room temperature for 2 hours,the solvents were removed under reduced pressure to provide 129. 129 (¹HNMR (300 MHz, CDCl₃) δ: 7.89 (d, 1H, J=8.2), 5.75 (d, 1H, J=8.2), 5.63(s, 1H), 4.22 (s, 1H), 4.17 (s, 1H), 4.08 (m, 1H), 3.98 (d, 1H, J=7.6),3.71 (d, 1H, J=7.6), 3.60 (t, 1H, J=9.1), 3.44 (s, 3H), 3.42 (m, 1H,overlapped), 0.88 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H).

B) Preparation of Compound 141

Compound 129 is converted to phosphoramidite compound 141 using the samegeneral procedures described for the preparation of phosphoramiditecompound 19a from 16a in example 1

C) Preparation of Compounds 142-144

Compounds 130-132 are prepared by hydrogenation of the benzyloxymethylprotecting group using catalytic palladium on carbon and hydrogen gas.Protection of the 5′ hydroxyl group as the dimethoxytrityl etherfollowed by removal of the silyl protecting group and a phosphitylationreaction (as described in example 1) provides phosphoramidite Compounds142-144.

Example 20 Preparation of Compounds 159 and 160

Compound 48 is prepared as per the procedures illustrated in Example 9.

Example 21 Preparation of Compounds 175 and 176

Compound 145 is prepared as per the procedures illustrated in Example20.

Example 22 Synthesis of Nucleoside Phosphoramidites

The preparation of nucleoside phosphoramidites is performed followingprocedures that are illustrated herein and in the art such as but notlimited to U.S. Pat. No. 6,426,220 and published PCT WO 02/36743.

Example 23 Oligonucleotide and Oligonucleoside Synthesis

The oligomeric compounds used in accordance with this invention may beconveniently and routinely made through the well-known technique ofsolid phase synthesis. Equipment for such synthesis is sold by severalvendors including, for example, Applied Biosystems (Foster City,Calif.). Any other means for such synthesis known in the art mayadditionally or alternatively be employed. It is well known to usesimilar techniques to prepare oligonucleotides such as thephosphorothioates and alkylated derivatives.

Oligonucleotides: Unsubstituted and substituted phosphodiester (P═O)oligonucleotides can be synthesized on an automated DNA synthesizer(Applied Biosystems model 394) using standard phosphoramidite chemistrywith oxidation by iodine.

Phosphorothioates (P═S) are synthesized similar to phosphodiesteroligonucleotides with the following exceptions: thiation is effected byutilizing a 10% w/v solution of 3,H-1,2-benzodithiole-3-one 1,1-dioxidein acetonitrile for the oxidation of the phosphite linkages. Thethiation reaction step time is increased to 180 sec and preceded by thenormal capping step. After cleavage from the CPG column and deblockingin concentrated ammonium hydroxide at 55° C. (12-16 hr), theoligonucleotides are recovered by precipitating with >3 volumes ofethanol from a 1 M NH₄OAc solution. Phosphinate oligonucleotides can beprepared as described in U.S. Pat. No. 5,508,270.

Alkyl phosphonate oligonucleotides can be prepared as described in U.S.Pat. No. 4,469,863.

3′-Deoxy-3′-methylene phosphonate oligonucleotides can be prepared asdescribed in U.S. Pat. No. 5,610,289 or 5,625,050.

Phosphoramidite oligonucleotides can be prepared as described in U.S.Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878.

Alkylphosphonothioate oligonucleotides can be prepared as described inpublished PCT applications PCT/US94/00902 and PCT/US93/06976 (publishedas WO 94/17093 and WO 94/02499, respectively).

3′-Deoxy-3′-amino phosphoramidate oligonucleotides can be prepared asdescribed in U.S. Pat. No. 5,476,925.

Phosphotriester oligonucleotides can be prepared as described in U.S.Pat. No. 5,023,243.

Borano phosphate oligonucleotides can be prepared as described in U.S.Pat. Nos. 5,130,302 and 5,177,198.

Oligonucleosides: Methylenemethylimino linked oligonucleosides, alsoidentified as MMI linked oligonucleosides, methylenedimethylhydrazolinked oligonucleosides, also identified as MDH linked oligonucleosides,and methylenecarbonylamino linked oligonucleosides, also identified asamide-3 linked oligonucleosides, and methyleneaminocarbonyl linkedoligonucleosides, also identified as amide-4 linked oligonucleosides, aswell as mixed backbone oligomeric compounds having, for instance,alternating MMI and P═O or P═S linkages can be prepared as described inU.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289.

Formacetal and thioformacetal linked oligonucleosides can be prepared asdescribed in U.S. Pat. Nos. 5,264,562 and 5,264,564.

Ethylene oxide linked oligonucleosides can be prepared as described inU.S. Pat. No. 5,223,618.

Example 24 Oligonucleotide Isolation

After cleavage from the controlled pore glass solid support anddeblocking in concentrated ammonium hydroxide at 55° C. for 12-16 hours,the oligonucleotides or oligonucleosides are recovered by precipitationout of 1 M NH₄OAc with >3 volumes of ethanol. Synthesizedoligonucleotides are analyzed by electrospray mass spectroscopy(molecular weight determination) and by capillary gel electrophoresis.The relative amounts of phosphorothioate and phosphodiester linkagesobtained in the synthesis is determined by the ratio of correctmolecular weight relative to the −16 amu product (+/−32+/−48). For somestudies oligonucleotides are purified by HPLC, as described by Chiang etal., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained withHPLC-purified material are generally similar to those obtained withnon-HPLC purified material.

Example 25 Oligonucleotide Synthesis 96 Well Plate Format

Oligonucleotides can be synthesized via solid phase P(III)phosphoramidite chemistry on an automated synthesizer capable ofassembling 96 sequences simultaneously in a 96-well format.Phosphodiester internucleotide linkages are afforded by oxidation withaqueous iodine. Phosphorothioate internucleotide linkages are generatedby sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide(Beaucage Reagent) in anhydrous acetonitrile. Standard base-protectedbeta-cyanoethyl-diiso-propyl phosphoramidites are purchased fromcommercial vendors (e.g. PE-Applied Biosystems, Foster City, Calif., orPharmacia, Piscataway, N.J.). Non-standard nucleosides are synthesizedas per standard or patented methods. They are utilized as base protectedbeta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides are cleaved from support and deprotected withconcentrated NH₄OH at elevated temperature (55-60° C.) for 12-16 hoursand the released product then dried in vacuo. The dried product is thenre-suspended in sterile water to afford a master plate from which allanalytical and test plate samples are then diluted utilizing roboticpipettors.

Example 26 Oligonucleotide Analysis Using 96-Well Plate Format

The concentration of oligonucleotide in each well is assessed bydilution of samples and UV absorption spectroscopy. The full-lengthintegrity of the individual products is evaluated by capillaryelectrophoresis (CE) in either the 96-well format (Beckman P/ACE™ MDQ)or, for individually prepared samples, on a commercial CE apparatus(e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition isconfirmed by mass analysis of the oligomeric compounds utilizingelectrospray-mass spectroscopy. All assay test plates are diluted fromthe master plate using single and multi-channel robotic pipettors.Plates are judged to be acceptable if at least 85% of the oligomericcompounds on the plate are at least 85% full length.

Example 27 Cell Culture and Oligonucleotide Treatment

The effect of oligomeric compounds on target nucleic acid expression canbe tested in any of a variety of cell types provided that the targetnucleic acid is present at measurable levels. This can be routinelydetermined using, for example, PCR or Northern blot analysis. Cell linesderived from multiple tissues and species can be obtained from AmericanType Culture Collection (ATCC, Manassas, Va.).

The following cell type is provided for illustrative purposes, but othercell types can be routinely used, provided that the target is expressedin the cell type chosen. This can be readily determined by methodsroutine in the art, for example Northern blot analysis, ribonucleaseprotection assays or RT-PCR.

b.END cells: The mouse brain endothelial cell line b.END was obtainedfrom Dr. Werner Risau at the Max Plank Institute (Bad Nauheim, Germany).b.END cells were routinely cultured in DMEM, high glucose (InvitrogenLife Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovineserum (Invitrogen Life Technologies, Carlsbad, Calif.). Cells wereroutinely passaged by trypsinization and dilution when they reachedapproximately 90% confluence. Cells were seeded into 96-well plates(Falcon-Primaria #353872, BD Biosciences, Bedford, Mass.) at a densityof approximately 3000 cells/well for uses including but not limited tooligomeric compound transfection experiments.

Experiments involving treatment of cells with oligomeric compounds:

When cells reach appropriate confluency, they are treated witholigomeric compounds using a transfection method as described.

LIPOFECTIN™

When cells reached 65-75% confluency, they are treated witholigonucleotide. Oligonucleotide is mixed with LIPOFECTIN™ InvitrogenLife Technologies, Carlsbad, Calif.) in Opti-MEM™-1 reduced serum medium(Invitrogen Life Technologies, Carlsbad, Calif.) to achieve the desiredconcentration of oligonucleotide and a LIPOFECTIN™ concentration of 2.5or 3 μg/mL per 100 nM oligonucleotide. This transfection mixture isincubated at room temperature for approximately 0.5 hours. For cellsgrown in 96-well plates, wells are washed once with 100 μL OPTI-MEM™-1and then treated with 130 μL of the transfection mixture. Cells grown in24-well plates or other standard tissue culture plates are treatedsimilarly, using appropriate volumes of medium and oligonucleotide.Cells are treated and data are obtained in duplicate or triplicate.After approximately 4-7 hours of treatment at 37° C., the mediumcontaining the transfection mixture is replaced with fresh culturemedium. Cells are harvested 16-24 hours after oligonucleotide treatment.

Other suitable transfection reagents known in the art include, but arenot limited to, CYTOFECTIN™, LIPOFECTAMINE™, OLIGOFECTAMINE™, andFUGENE™. Other suitable transfection methods known in the art include,but are not limited to, electroporation.

Example 28 Analysis of Oligonucleotide Inhibition of a Target Expression

Antisense modulation of a target expression can be assayed in a varietyof ways known in the art. For example, a target mRNA levels can bequantitated by, e.g., Northern blot analysis, competitive polymerasechain reaction (PCR), or real-time PCR. Real-time quantitative PCR ispresently desired. RNA analysis can be performed on total cellular RNAor poly(A)+ mRNA. One method of RNA analysis of the present invention isthe use of total cellular RNA as described in other examples herein.Methods of RNA isolation are well known in the art. Northern blotanalysis is also routine in the art. Real-time quantitative (PCR) can beconveniently accomplished using the commercially available ABI PRISM™7600, 7700, or 7900 Sequence Detection System, available from PE-AppliedBiosystems, Foster City, Calif. and used according to manufacturer'sinstructions.

Protein levels of a target can be quantitated in a variety of ways wellknown in the art, such as immunoprecipitation, Western blot analysis(immunoblotting), enzyme-linked immunosorbent assay (ELISA) orfluorescence-activated cell sorting (FACS). Antibodies directed to atarget can be identified and obtained from a variety of sources, such asthe MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.),or can be prepared via conventional monoclonal or polyclonal antibodygeneration methods well known in the art. Methods for preparation ofpolyclonal antisera are taught in, for example, Ausubel, F. M. et al.,Current Protocols in Molecular Biology, Volume 2, pp. 11.12.1-11.12.9,John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies istaught in, for example, Ausubel, F. M. et al., Current Protocols inMolecular Biology, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons,Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at,for example, Ausubel, F. M. et al., Current Protocols in MolecularBiology, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998.Western blot (immunoblot) analysis is standard in the art and can befound at, for example, Ausubel, F. M. et al., Current Protocols inMolecular Biology, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons,Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard inthe art and can be found at, for example, Ausubel, F. M. et al., CurrentProtocols in Molecular Biology, Volume 2, pp. 11.2.1-11.2.22, John Wiley& Sons, Inc., 1991.

Example 29 Design of Phenotypic Assays and In Vivo Studies for the Useof Target Inhibitors

Phenotypic Assays

Once target inhibitors have been identified by the methods disclosedherein, the oligomeric compounds are further investigated in one or morephenotypic assays, each having measurable endpoints predictive ofefficacy in the treatment of a particular disease state or condition.

Phenotypic assays, kits and reagents for their use are well known tothose skilled in the art and are herein used to investigate the roleand/or association of a target in health and disease. Representativephenotypic assays, which can be purchased from any one of severalcommercial vendors, include those for determining cell viability,cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene,Oreg.; PerkinElmer, Boston, Mass.), protein-based assays includingenzymatic assays (Panvera, LLC, Madison, Wis.; BD Biosciences, FranklinLakes, N.J.; Oncogene Research Products, San Diego, Calif.), cellregulation, signal transduction, inflammation, oxidative processes andapoptosis (Assay Designs Inc., Ann Arbor, Mich.), triglycerideaccumulation (Sigma-Aldrich, St. Louis, Mo.), angiogenesis assays, tubeformation assays, cytokine and hormone assays and metabolic assays(Chemicon International Inc., Temecula, Calif.; Amersham Biosciences,Piscataway, N.J.).

In one non-limiting example, cells determined to be appropriate for aparticular phenotypic assay (i.e., MCF-7 cells selected for breastcancer studies; adipocytes for obesity studies) are treated with atarget inhibitors identified from the in vitro studies as well ascontrol compounds at optimal concentrations which are determined by themethods described above. At the end of the treatment period, treated anduntreated cells are analyzed by one or more methods specific for theassay to determine phenotypic outcomes and endpoints.

Phenotypic endpoints include changes in cell morphology over time ortreatment dose as well as changes in levels of cellular components suchas proteins, lipids, nucleic acids, hormones, saccharides or metals.Measurements of cellular status which include pH, stage of the cellcycle, intake or excretion of biological indicators by the cell, arealso endpoints of interest.

Measurement of the expression of one or more of the genes of the cellafter treatment is also used as an indicator of the efficacy or potencyof the a target inhibitors. Hallmark genes, or those genes suspected tobe associated with a specific disease state, condition, or phenotype,are measured in both treated and untreated cells.

In Vivo Studies

The individual subjects of the in vivo studies described herein arewarm-blooded vertebrate animals, which includes humans.

Example 30 RNA Isolation

Poly(A)+ mRNA Isolation

Poly(A)+ mRNA is isolated according to Miura et al., (Clin. Chem., 1996,42, 1758-1764). Other methods for poly(A)+ mRNA isolation are routine inthe art. Briefly, for cells grown on 96-well plates, growth medium isremoved from the cells and each well is washed with 200 μL cold PBS. 60μL lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5%NP-40, 20 mM vanadyl-ribonucleoside complex) is added to each well, theplate is gently agitated and then incubated at room temperature for fiveminutes. 55 μL of lysate is transferred to Oligo d(T) coated 96-wellplates (AGCT Inc., Irvine Calif.). Plates are incubated for 60 minutesat room temperature, washed 3 times with 200 μL of wash buffer (10 mMTris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plateis blotted on paper towels to remove excess wash buffer and thenair-dried for 5 minutes. 60 μL of elution buffer (5 mM Tris-HCl pH 7.6),preheated to 70° C., is added to each well, the plate is incubated on a90° C. hot plate for 5 minutes, and the eluate is then transferred to afresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly,using appropriate volumes of all solutions.

Total RNA Isolation

Total RNA is isolated using an RNEASY 96™ kit and buffers purchased fromQiagen Inc. (Valencia, Calif.) following the manufacturer's recommendedprocedures. Briefly, for cells grown on 96-well plates, growth medium isremoved from the cells and each well is washed with 200 μL cold PBS. 150μL Buffer RLT is added to each well and the plate vigorously agitatedfor 20 seconds. 150 μL of 70% ethanol is then added to each well and thecontents mixed by pipetting three times up and down. The samples arethen transferred to the RNEASY 96™ well plate attached to a QIAVAC™manifold fitted with a waste collection tray and attached to a vacuumsource. Vacuum is applied for 1 minute. 500 μL of Buffer RW1 is added toeach well of the RNEASY 96™ plate and incubated for 15 minutes and thevacuum is again applied for 1 minute. An additional 500 μL of Buffer RW1is added to each well of the RNEASY 96™ plate and the vacuum is appliedfor 2 minutes. 1 mL of Buffer RPE is then added to each well of theRNEASY 96™ plate and the vacuum applied for a period of 90 seconds. TheBuffer RPE wash is then repeated and the vacuum is applied for anadditional 3 minutes. The plate is then removed from the QIAVAC™manifold and blotted dry on paper towels. The plate is then re-attachedto the QIAVAC™ manifold fitted with a collection tube rack containing1.2 mL collection tubes. RNA is then eluted by pipetting 140 μL of RNAsefree water into each well, incubating 1 minute, and then applying thevacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using aQIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia Calif.). Essentially,after lysing of the cells on the culture plate, the plate is transferredto the robot deck where the pipetting, DNase treatment and elution stepsare carried out.

Example 31 Real-Time Quantitative PCR Analysis of Target mRNA Levels

Quantitation of a target mRNA levels was accomplished by real-timequantitative PCR using the ABI PRISM™ 7600, 7700, or 7900 SequenceDetection System (PE-Applied Biosystems, Foster City, Calif.) accordingto manufacturer's instructions. This is a closed-tube, non-gel-based,fluorescence detection system which allows high-throughput quantitationof polymerase chain reaction (PCR) products in real-time. As opposed tostandard PCR in which amplification products are quantitated after thePCR is completed, products in real-time quantitative PCR are quantitatedas they accumulate. This is accomplished by including in the PCRreaction an oligonucleotide probe that anneals specifically between theforward and reverse PCR primers, and contains two fluorescent dyes. Areporter dye (e.g., FAM or JOE, obtained from either PE-AppliedBiosystems, Foster City, Calif., Operon Technologies Inc., Alameda,Calif. or Integrated DNA Technologies Inc., Coralville, Iowa) isattached to the 5′ end of the probe and a quencher dye (e.g., TAMRA,obtained from either PE-Applied Biosystems, Foster City, Calif., OperonTechnologies Inc., Alameda, Calif. or Integrated DNA Technologies Inc.,Coralville, Iowa) is attached to the 3′ end of the probe. When the probeand dyes are intact, reporter dye emission is quenched by the proximityof the 3′ quencher dye. During amplification, annealing of the probe tothe target sequence creates a substrate that can be cleaved by the5′-exonuclease activity of Taq polymerase. During the extension phase ofthe PCR amplification cycle, cleavage of the probe by Taq polymerasereleases the reporter dye from the remainder of the probe (and hencefrom the quencher moiety) and a sequence-specific fluorescent signal isgenerated. With each cycle, additional reporter dye molecules arecleaved from their respective probes, and the fluorescence intensity ismonitored at regular intervals by laser optics built into the ABI PRISM™Sequence Detection System. In each assay, a series of parallel reactionscontaining serial dilutions of mRNA from untreated control samplesgenerates a standard curve that is used to quantitate the percentinhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to thetarget gene being measured are evaluated for their ability to be“multiplexed” with a GAPDH amplification reaction. In multiplexing, boththe target gene and the internal standard gene GAPDH are amplifiedconcurrently in a single sample. In this analysis, mRNA isolated fromuntreated cells is serially diluted. Each dilution is amplified in thepresence of primer-probe sets specific for GAPDH only, target gene only(“single-plexing”), or both (multiplexing). Following PCR amplification,standard curves of GAPDH and target mRNA signal as a function ofdilution are generated from both the single-plexed and multiplexedsamples. If both the slope and correlation coefficient of the GAPDH andtarget signals generated from the multiplexed samples fall within 10% oftheir corresponding values generated from the single-plexed samples, theprimer-probe set specific for that target is deemed multiplexable. Othermethods of PCR are also known in the art.

RT and PCR reagents were obtained from Invitrogen Life Technologies(Carlsbad, Calif.). RT, real-time PCR was carried out by adding 20 μLPCR cocktail (2.5×PCR buffer minus MgCl₂, 6.6 mM MgCl₂, 375 μM each ofdATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverseprimer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM®Taq, 5 Units MuLV reverse transcriptase, and 2.5×ROX dye) to 96-wellplates containing 30 μL total RNA solution (20-200 ng). The RT reactionwas carried out by incubation for 30 minutes at 48° C. Following a 10minute incubation at 95° C. to activate the PLATINUM® Taq, 40 cycles ofa two-step PCR protocol were carried out: 95° C. for 15 seconds(denaturation) followed by 60° C. for 1.5 minutes (annealing/extension).

Gene target quantities obtained by RT, real-time PCR are normalizedusing either the expression level of GAPDH, a gene whose expression isconstant, or by quantifying total RNA using RIBOGREEN™ (MolecularProbes, Inc. Eugene, Oreg.). GAPDH expression is quantified by real timeRT-PCR, by being run simultaneously with the target, multiplexing, orseparately. Total RNA is quantified using RiboGreen™ RNA quantificationreagent (Molecular Probes, Inc. Eugene, Oreg.). Methods of RNAquantification by RIBOGREEN™ are taught in Jones, L. J., et al,(Analytical Biochemistry, 1998, 265, 368-374).

In this assay, 170 μL of RIBOGREEN™ working reagent (RIBOGREEN™ reagentdiluted 1:350 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a96-well plate containing 30 μL purified, cellular RNA. The plate is readin a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485 nmand emission at 530 nm.

Example 32 Target-Specific Primers and Probes

Probes and primers may be designed to hybridize to a target sequence,using published sequence information.

For example, for human PTEN, the following primer-probe set was designedusing published sequence information (GENBANK™ accession numberU92436.1, SEQ ID NO: 1).

(SEQ ID NO: 2) Forward primer: AATGGCTAAGTGAAGATGACAATCAT (SEQ ID NO: 3)Reverse primer: TGCACATATCATTACACCAGTTCGTAnd the PCR probe:

FAM-TTGCAGCAATTCACTGTAAAGCTGGAAAGG-TAMRA (SEQ ID NO: 4), where FAM isthe fluorescent dye and TAMRA is the quencher dye.

Example 33 Western Blot Analysis of Target Protein Levels

Western blot analysis (immunoblot analysis) is carried out usingstandard methods. Cells are harvested 16-20 h after oligonucleotidetreatment, washed once with PBS, suspended in Laemmli buffer (100μl/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gelsare run for 1.5 hours at 150 V, and transferred to membrane for westernblotting. Appropriate primary antibody directed to a target is used,with a radiolabeled or fluorescently labeled secondary antibody directedagainst the primary antibody species. Bands are visualized using aPHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale Calif.).

Example 34 Preparation of Oligomeric Compounds

Following synthetic procedures well know in the art, some of which areillustrated herein, oligomeric compounds are prepared having at leastone bis-modified bicyclic nucleoside having Formula III, using one ormore of the phosphoramidite compounds 159, 160, 175 or 175 illustratedin Examples 20 and 21.

Example 35 Nuclease Stability of 5′-(S) and (R)—CH₃—BNA ModifiedOligomers Treated with SVPD

The nuclease stability of 5′-CH₃—BNA modified oligomers was determinedusing snake venom phosphodiesterase (SVPD). Each oligomer was preparedas a 500 μL mixture containing: 5 μL 100 μM oligomer, 50 μLphosphodiesterase I@0.5 Units/mL in SVPD buffer (50 mM Tris-HcL, pH 7.5,8 mM MgCl₂) final concentration 0.05 Units/mL, 445 μL SVP buffer.Samples were incubated at 37° C. in a water bath. Aliquats (100 μL) weretaken at 0, 1, 2 and 4 days with fresh enzyme added at days 1 and 2.EDTA was added to aliquats immediately after removal to quench enzymeactivity. Samples were analyzed on IP HPLC/MS.

SEQ ID NO./ Composition % full length ISIS NO. (5′ to 3′) at day 405/392747 C_(S)U_(S)TAGCACTGGCC_(S)U_(S) >80 05/392746C_(R)U_(R)TAGCACTGGCC_(R)U_(R) >80 05/392745C_(l)U_(l)TAGCACTGGCC_(l)U_(l) 40-50 05/392753C_(e)U_(e)TAGCACTGGCC_(e)U_(e) 30-40

All internucleoside linkages are phosphodiester, subscript S or Rindicates the configuration at the 5′ carbon atom for 5′-CH₃—BNAnucleosides which also have a 4′-CH₂—O-2′ bridge group. A subscript eindicates 2′-O-MOE nucleosides and subscript 1 indicates 4′-CH₂—O-2′modified nucleosides. The 5-methyl substituted BNA-containing compounds(392746 and 392747) had a marked improvement over the unsubstitutedBNA-containing compound (392745).

SEQ ID NO./ % Composition % Composition % Composition ISIS NO. at 24hours at 48 hours at 96 hours 05/392747 100% 86% 82% 05/392746 100% 90% 84%. 05/392745  67% 56% 48% 05/392753  58% 46%  36%.

Example 36 Nuclease Stability of 5′-(S)—CH₃—BNA and 2′-O-MOE ModifiedOligomers Treated with SVPD

The nuclease stability of 5′-CH₃—BNA modified oligomers was determinedusing snake venom phosphodiesterase (SVPD). Each oligomer was preparedas a 90 μL mixture containing 5 μL oligomer (2 μL of 5 μM oligomer and 3μL of 5′ ³²P-labeled oligomer) 75 μL H₂O, and 10 μL 10× buffer (500 mMTris-HCl, 700 mM NaCl, and 140 mM MgCl₂ at pH 8.6). At time equals 0min, 9 μL were removed from the oligomer sample prepared above and addedto 10 μL stop buffer (6.67 M urea, 16.67% formamide and 83.3 mM EDTA)followed by 1 μL of H₂O and heated at 100° C. for 2.5 to 3 min. Thekinetics of the assay began by the addition of 9 μL of SVPD (0.5Units/mL). Final enzyme concentration was 0.05 Units/mL. Each aliquot of10 μL of oligomer kinetics solution were added to 10 μL of stop bufferand heat deactivated as described above. Kinetic time points were takenat 1, 3, 9, 27, 80, 240 and 1290 min. Samples were analyzed by 12%acrylomide PAGE run for 2 hours at 45 Watts/gel.

SEQ ID NO./ Composition ISIS NO. (5′ to 3′) modification 06/395421TTTTTTTTTTT_(e)T_(e) 2′-O-MOE 07/395423 TTTTTTTTTTU_(l)U_(l) 4′-CH₂—O-2′07/395427 TTTTTTTTTTU_(S)U_(S) 5′-(S)—CH₃ BNA 06/7157 TTTTTTTTTTTTunmodified (2′-H)

All internucleoside linkages are phosphodiester, subscript S indicatesthe configuration at the 5′ carbon atom for 5′-CH₃—BNA nucleosides whichalso have a 4′-CH₂—O-2′ bridge group, subscript e indicates 2′-O-MOEnucleosides and subscript 1 indicates 4′-CH₂—O-2′ BNAs. All nonsubscripted T's are 2′-H. The 5-methyl substituted BNA-containingcompound (395427) had a marked improvement over the unsubstitutedBNA-containing compound (395423) and the MOE-containing compound(395421).

% Comp. % Comp. % Comp. % Comp. % Comp. SEQ ID NO. at 3 at 27 at 80 at240 at 1290 ISIS No. min. min. min. min. min. 06/395421 68.7 27.9 17.211.6 9.0 07/395423 32.6 4.7 2.5 2.2 2.2 07/395427 100.0 91.6 86.6 76.061.1  06/7157 5.2 1.2 2.0 1.7  0.9.

Example 37 5′-(S)—CH₃—BNA and 5′-(R)—CH₃—BNA 2-10-2 Gapped OligomersTargeted to PTEN: In Vitro Study

In accordance with the present invention, oligomeric compounds weresynthesized and tested for their ability to reduce PTEN expression overa range of doses. b.END cells were treated with the 5′-CH₃—BNA modifiedoligomers at concentrations of 0.3125, 0.0625, 1.25, 2.5, 5, 10 or 20 nMusing methods described herein. Expression levels of PTEN weredetermined using real-time PCR and normalized to RIBOGREEN™ as describedin other examples herein. The percent reduction of PTEN mRNA relative tountreated control cells (% UTC) at a drug concentration of 20 nM istabulated below. Resulting dose-response curves were used to determinethe IC50 of 392747 as shown below. Tm's were assessed in 100 mMphosphate buffer, 0.1 mM EDTA, pH 7, at 260 nm using 4 μM 5′-CH₃—BNAmodified oligomers and 4 μM complementary RNA.

SEQ ID NO./ Composition % Tm ISIS NO. (5′ to 3′) UTC IC₅₀ ° C. 05/392746C_(R)U_(R)TAGCACTGGCC_(R)U_(R) 75 47.3 05/392747C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 28 8.6 57.0

All internucleoside linkages are phosphorothioate and subscripts R and Sindicate the configuration at the 5′ carbon atom for 5′-CH₃—BNAnucleosides which also have a 4′-CH₂—O-2′ bridge group.

Example 38 5′-(S)—CH₃—BNA and 5′-(R)—CH₃—BNA 2-10-2 Gapped OligomersTargeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected twice weekly for 3 weeks with a 5′-CH₃—BNA modified oligomers(either 5′-(S) or 5′-(R)) targeted to PTEN at a dose of 0.5 or 2μmol/kg. The mice were sacrificed 48 hours following the finaladministration. Liver tissues were homogenized and mRNA levels werequantitated using real-time PCR as described herein for comparison tountreated control levels (% UTC).

SEQ ID NO./ Composition dose % ISIS NO. (5′ to 3′) (μmol/kg) UTC saline100 05/392746 C_(R)U_(R)TAGCACTGGCC_(R)U_(R) 2.0 56 05/392746C_(R)U_(R)TAGCACTGGCC_(R)U_(R) 0.5 71 05/392747C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 2.0 28 05/392747C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 0.5 91

All internucleoside linkages are phosphorothioate and subscripts R and Sindicates the configuration at the 5′ carbon atom for 5′-CH₃—BNAnucleosides which also have a 4′-CH₂—O-2′ bridge group.

Example 39 5′-(S)—CH₃—BNA 2-10-2 Gapped Oligomers Targeted to PTEN: InVivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with a 5′-(S)—CH₃—BNA modified oligomer targeted to PTENat a dose of 1, 2, 4 or 8 μmol/kg. The mice were sacrificed 72 hrsfollowing administration. Liver tissues were homogenized and mRNA levelswere quantitated using real-time PCR as described herein for comparisonto untreated control levels (% UTC).

SEQ ID NO./ Composition dose % ISIS NO. (5′ to 3′) (μmol/kg) UTC saline100 05/392747 C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 1 92 05/392747C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 2 65 05/392747C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 4 33 05/392747C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 8 13

All internucleoside linkages are phosphorothioate and subscript Sindicates the configuration at the 5′ carbon atom for 5′-CH₃—BNAnucleosides which also have a 4′-CH₂—O-2′ bridge group.

Example 40 5′-(S)—CH₃—BNA and 2′-O-MOE Gapped Oligomers Targeted to PTENin a Three-Week, Multiple Dose In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected twice weekly for three weeks with 5′-(S)—CH₃—BNA (2-10-2,14-mer), 4′-CH₂—O-2′-BNA (2-10-2, 14-mer) and 2′-O-MOE (5-10-5, 20-mer)modified oligomers targeted to PTEN at a dose of 3.2, 1.0, 0.32 and 0.1μmol/kg (only the 3.2 and 1 μmol/kg data is shown below). The mice weresacrificed 48 hrs following last administration. Liver tissues werehomogenized and mRNA levels were quantitated using real-time PCR asdescribed herein for comparison to untreated control levels (% UTC).Plasma chemistries and liver weights were determined after sacrifice.

dose SEQ ID NO./ Composition (μmol/ % ISIS NO. (5′ to 3′) kg) UTC ALTsaline 05/392747 C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 3.2 15 17.5 05/392747C_(S)U_(S)TAGCACTGGCC_(S)U_(S) 1 53 21.3 08/392063^(Me)C_(l)T_(l)AGCACTGGC^(Me)C_(l)T_(l) 3.2 4.2 279.3 08/392063^(Me)C_(l)T_(l)AGCACTGGC^(Me)C_(l)T_(l) 1 26 41.0 09/116847^(Me)C_(e)T_(e)G_(e) ^(Me)C_(e)T_(e)AG^(Me)C 1 53 41.3^(Me)CT^(Me)CTGGAT_(e)T_(e)T_(e)G_(e)A_(e)

All internucleoside linkages are phosphorothioate, subscript S indicatesthe configuration at the 5′ carbon atom for 5′-CH₃—BNA nucleosides whichalso have a 4′-CH₂—O-2′ bridge group, subscript 1 indicates a4′-CH₂—O-2′ BNA, subscript e indicates a 2′-O-MOE and ^(Me)C indicates a5′-methyl cytosine nucleoside.

At the culmination of the study, animals in the high dose group showedsignificant increase in liver weights for the 4′-CH₂—O-2′ BNA (392063,3.2 μmol/Kg dose group) containing oligomers (153% relative to saline).In contrast, the liver weights for 5′-(S)—CH₃ BNA (392747, 3.2 μmol/Kgdose group) containing oligomers were 121% relative to saline. Liverweights for 2′-O-MOE containing oligomers (116847, 1.0 μmol/Kg dosegroup) were 116% relative to saline. This example demonstrates that the5′-(S)—CH₃—BNA modification allows for the design of antisense oligomerswhich show a dramatic improvement in the ALT levels over the 4′-CH₂—O-2′BNA modified compounds.

Example 41 5′(S)-Me-BNA and 4′-CH₂—O-2′ BNA 2-10-2 Gapped OligomersTargeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with modified 5′-(S)—CH₃ (396569), 4′-CH₂—O-2′ BNA 2-10-2gapped oligomers targeted to PTEN at a dose of 2.5, 5, 10 and 20 μmol/kg(only 5 and 10 μmol/Kg data shown). The mice were sacrificed 66 hrsfollowing administration. Liver tissues were homogenized.

SEQ ID NO./ Composition dose ISIS NO. (5′ to 3′) (μmol/kg) ALT saline41.3 10/396569 U_(S)C_(S)ATGGCTGCAGC_(S)U_(S) 10 111.0 10/396569U_(S)C_(S)ATGGCTGCAGC_(S)U_(S) 5 54.0 11/392056 T_(l)^(Me)C_(l)ATGGCTGCAG^(Me)C_(l)T_(l) 10 925.0 11/392056 T_(l)^(Me)C_(l)ATGGCTGCAG^(Me)C_(l)T_(l) 5 373.0

All internucleoside linkages are phosphorothioate, subscript S indicatesthe configuration at the 5′ carbon atom for 5′-CH₃—BNA nucleosides whichalso have a 4′-CH₂—O-2′ bridge group, subscript 1 indicates 4′-CH₂—O-2′nucleosides and ^(Me)C indicates a 5′-methyl cytosine nucleoside.

For the above oligonucleotides, one (Isis No. 392056) does not include anucleoside that is chiral at the 5′ carbon atom, wherein the 396569does. 396569 includes a 5′(S)-Me monomer and is clearly less toxic inthe liver as compared to 392056 which does not have a substituent at the5′-position.

Example 42 5′(S)-Me-BNA, 2′-O-MOE and 4′-CH₂—O-2′ BNA 2-14-2 GappedOligomers Targeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with 5′-CH₃—BNA modified oligomers targeted to PTEN at adose of 2 or 10 μmol/kg. The mice were sacrificed 72 hrs followingadministration. Liver tissues were homogenized and mRNA levels werequantitated using real-time PCR as described herein for comparison tountreated control levels (% UTC).

SEQ ID NO./ Composition ISIS NO. (5′ to 3′) modification 12/394420^(Me)C_(e)T_(e)GCTAGCCTCTGGATT_(e)T_(e) 2′-O-MOE 12/394425^(Me)C_(l)T_(l)GCTAGCCTCTGGATT_(l)T_(l) 4′-CH₂—O-2′BNA 13/400521C_(S)U_(S)GCTAGCCTCTGGATU_(S)U_(S) 5′-(S)—CH₃ dose % ISIS NO. (μmol/kg)UTC ALT saline  100% 38.5 394420 2   79% 30.3 394420 10   26% 49.3394425 2   11% 41.2 394425 10  2.1% 2453.2 400521 2 21.4% 36.7 400521 10 3.8% 152

All internucleoside linkages are phosphorothioate, subscripts R and Sindicate the configuration at the 5′ carbon atom for 5′-CH₃—BNAnucleosides which also have a 4′-CH₂—O-2′ bridge group, subscript eindicates 2′-O-MOE nucleosides, subscript 1 indicates 4′-CH₂—O-2′nucleosides and ^(Me)C indicates a 5′-methyl cytosine nucleoside.

At the high dose group (10 micromole/Kg), oligonucleotide 400521containing the 5′(S)-Me modification is essentially equally efficaciousas 394425. However, the ALT elevations for 400521 are modest (152) ascompared to 394425 (2453.2) clearly indicating that the 5′-substitutionresults in a greatly improved therapeutic index.

Example 43 6-(S)—CH₃—BNA and 6-(R)—CH₃—BNA 2-10-2 Gapped OligomersTargeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected twice weekly for 3 weeks with a 6-CH₃—BNA modified oligomers(either 6-(S) or 6-(R)) targeted to PTEN at a dose of 0.5 or 2 μmol/kg.The mice were sacrificed 48 hours following the final administration.Liver tissues were homogenized and mRNA levels were quantitated usingreal-time PCR as described herein for comparison to untreated controllevels (% UTC).

SEQ ID NO./ Composition dose % ISIS NO. (5′ to 3′) (μmol/kg) UTC saline100 05/392748 C R U RTAGCACTGGCC R U R 2.0 31 05/392748 C R URTAGCACTGGCC R U R 0.5 81 05/392749 C S C STAGCACTGGCC S C S 2.0 2305/392749 C S C STAGCACTGGCC S C S 0.5 73

All internucleoside linkages are phosphorothioate, bolded nucleosidesare 6-CH₃—BNA nucleosides and subscripts R and S indicate theconfiguration at the 6 carbon atom.

Example 44 6-(S)—CH₃—BNA and 6-(R)—CH₃—BNA 2-10-2 Gapped OligomersTargeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with 6-CH₃—BNA modified oligomers (either 6-(S) or 6-(R))targeted to PTEN at a dose of 1, 2, 4 or 8 μmol/kg. The mice weresacrificed 72 hrs following administration. Liver tissues werehomogenized and mRNA levels were quantitated using real-time PCR asdescribed herein for comparison to untreated control levels (% UTC).

SEQ ID NO./ Composition dose % ISIS NO. (5′ to 3′) (μmol/kg) UTC saline100 05/392748 C R U RTAGCACTGGCC R U R 1 89 05/392748 C R U RTAGCACTGGCCR U R 2 66 05/392748 C R U RTAGCACTGGCC R U R 4 35 05/392748 C R URTAGCACTGGCC R U R 8 11 05/392749 C S C STAGCACTGGCC S C S 1 7505/392749 C S C STAGCACTGGCC S C S 2 51 05/392749 C S C STAGCACTGGCC S CS 4 25 05/392749 C S C STAGCACTGGCC S C S 8 9

All internucleoside linkages are phosphorothioate, bolded nucleosidesare 6-CH₃—BNA nucleosides and subscripts S and R indicate theconfiguration at the 6 carbon atom.

Example 45 6-(S)—CH₃—O—CH₂—BNA and 6-(R)—CH₃—O—CH₂—BNA 2-10-2 GappedOligomers Targeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with 6-CH₃—BNA modified oligomers (either 6-(S) or 6-(R))targeted to PTEN at a dose of 1, 2, 4 or 8 μmol/kg (only the 8 μmol/kgdata is shown below). The mice were sacrificed 72 hrs followingadministration. Liver tissues were homogenized and mRNA levels werequantitated using real-time PCR as described herein for comparison tountreated control levels (% UTC).

SEQ ID NO./ Composition dose % ISIS NO. (5′ to 3′) (μmol/kg) UTC saline100 05/396004

TAGCACTGGC

8 37 05/396005

TAGCACTGGC

8 37

All internucleoside linkages are phosphorothioate, bolded and underlinednucleosides are 6-CH₃—O—CH₂—BNA nucleosides and subscripts S and Rindicate the configuration at the 6 carbon atom.

Example 46 Nuclease Stability of 6-(R or S)—CH₃—BNA Modified OligomersTreated with SVPD

The nuclease stability of 6-(R or S)—CH₃—BNA (392748 and 392749respectively) modified oligomers was determined using snake venomphosphodiesterase (SVPD). The study included a the respective6-unsubstituted gapmer (4′-CH₂—O-2′ bridged BNA, 392745, subscript 1)and the 2′-O-MOE gapmer (2′-O—(CH₂)₂—OCH₃, 392753, subscript e) forcomparison. Each oligomer is prepared as a 500 μL mixture containing: 5μL 100 μM oligomer, 50 μL phosphodiesterase I @ 0.5 Units/mL in SVPDbuffer (50 mM Tris-HcL, pH 7.5, 8 mM MgCl₂) final concentration 0.05Units/mL, 445 μL SVP buffer. Samples were incubated at 37° C. in a waterbath. Aliquats (100 μL) were taken at 0, 1, 2 and 4 days with freshenzyme added at days 1 and 2. EDTA was added to aliquats immediatelyafter removal to quench enzyme activity. Samples were analyzed on IPHPLC/MS.

SEQ ID NO./ Composition % full length ISIS NO. (5′ to 3′) at day 405/392748 C R U RTAGCACTGGCC R U R >90 05/392749 C S U STAGCACTGGCC S US >70 05/392745 C l U lTAGCACTGGCC l U l >40 05/392753 C e UeTAGCACTGGCC e U e >30

SEQ ID NO./ % Composition % Composition % Composition ISIS NO. at 24hours at 48 hours at 96 hours 05/392748 100%  89% 92% 05/392749 96% 84%74% 05/392745 67% 56% 48% 05/392753 58% 46% 36%

All internucleoside linkages are phosphorothioate, bolded nucleosidesare modified nucleosides, subscript R and S indicate the configurationat the 6 carbon atom for 6-CH₃—BNA nucleosides, subscript e indicates2′-O-MOE nucleosides and subscript l indicates 4′-CH₂—O-2′ modifiednucleosides. The 6-methyl substituted BNA-containing compounds (392748and 392749) had a marked improvement over the unsubstitutedBNA-containing compound (392745).

Example 47 Nuclease Stability of 6-(R or S)—CH₃—BNA, 4′-CH₂—O-2′ BNA and2′-O-MOE Modified Oligomers Treated with SVPD

The nuclease stability of 6-CH₃—BNA modified oligomers was determinedusing snake venom phosphodiesterase (SVPD). Each oligomer is prepared asa 90 μL mixture containing 5 μL oligomer (2 μL of 5 μM oligomer and 3 μLof 5′ ³²P-labeled oligomer) 75 μL H₂O, and 10 μL 10× buffer (500 mMTris-HCl, 700 mM NaCl, and 140 mM MgCl₂ at pH 8.6). At time equals 0min, 9 μL were removed from the oligomer sample prepared above and addedto 10 μL stop buffer (6.67 M urea, 16.67% formamide and 83.3 mM EDTA)followed by 1 μL of H₂O and heated at 100° C. for 2.5 to 3 min. Thekinetics of the assay began by the addition of 9 μL of SVPD (0.5Units/mL). Final enzyme concentration was 0.05 Units/mL. Each aliquot of10 μL of oligomer kinetics solution were added to 10 μL of stop bufferand heat deactivated as described above. Kinetic time points were takenat 1, 3, 9, 27, 80, 240 and 1290 min. Samples were analyzed by 12%acrylomide PAGE run for 2 hours at 45 Watts/gel.

SEQ ID NO./ Composition ISIS NO. (5′ to 3′) modification 06/395421TTTTTTTTTTT e T e Bold 2′-O-MOE 07/395423 TTTTTTTTTTU l U lBold 4′-CH₂—O-2′ 07/395424 TTTTTTTTTTU R U R Bold 6-(R)—CH₃ 07/395425TTTTTTTTTTU S U S Bold 6-(S)—CH 06/7157 TTTTTTTTTTTT unmodified (2′-H)

All internucleoside linkages are phosphorothioate, bolded nucleosidesare modified nucleosides, subscript R and S indicate the configurationat the 6 carbon atom for 6-CH₃—BNA nucleosides, subscript e indicates2′-O-MOE nucleosides and subscript 1 indicates 4′-CH₂—O-2′ modifiednucleosides.

% Comp. % Comp. % Comp. % Comp. % Comp. SEQ ID NO. at 3 at 27 at 80 at240 at 1290 ISIS No. min. min. min. min. min. 06/395421 68.7 27.9 17.211.6 9.0 07/395423 32.6 4.7 2.5 2.2 2.2 07/395424 96.4 89.1 83.2 79.072.0 07/395425 96.0 86.3 83.7 82.3 82.7 06/7157 5.2 1.2 2.0 1.7 0.9.

Example 48 6-(S)—CH₃—BNA, 4′-CH₂—O-2-BNA, and 2′-O-MOE Gapped OligomersTargeted to PTEN in a Three-Week, Multiple Dose In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected twice weekly for three weeks with 6-(S)—CH₃—BNA (2-10-2,14-mer), 4′-CH₂—O-2′-BNA (2-10-2, 14-mer) and 2′-O-MOE (5-10-5, 20-mer)modified oligomers targeted to PTEN at a dose of 3.2, 1.0, 0.32 and 0.1μmol/kg (only the 3.2 and 1 μmol/kg data is shown below). The mice weresacrificed 48 hrs following last administration. Liver tissues werehomogenized and mRNA levels were quantitated using real-time PCR asdescribed herein for comparison to untreated control levels (% UTC).Plasma chemistries and liver weights were determined after sacrifice.

dose SEQ ID NO./ Composition (μmol/ % ISIS NO. (5′ to 3′) kg) UTC ALTsaline 100 41.3 05/392749 C S U STAGCACTGGCC S U S 3.2 4.3 29.805/392749 C S U STAGCACTGGCC S U S 1 36 24.5 08/392063 Me C l TlTAGCACTGGCMe C l T l 3.2 4.2 279.3 08/392063 Me C l T lTAGCACTGGCMe C lT l 1 26 41.0 09/116847 Me C e T e G e Me C e T eAG^(Me)C^(Me)CT 1 5341.3 ^(Me)CTGGAT e T e T e G e A e

All internucleoside linkages are phosphorothioate, bolded nucleosidesare modified positions, subscript s indicates 6-(S)—CH₃—BNA, subscript 1indicates a 4′-CH₂—O-2′ BNA, subscript e indicates a 2′-O-MOE and ^(Me)Cindicates a 5′-methyl cytosine nucleoside.

At the culmination of the study, animals in the high dose group showedsignificant increase in liver weights for the 4′-CH₂—O-2′ BNA (392063,3.2 μmol/Kg dose group) containing oligomers (153% relative to saline).In contrast, the liver weights for 6-(S)—CH₃ BNA (392749, 3.2 μmol/Kgdose group) containing oligomers were 117% relative to saline. Liverweights for 2′O-MOE containing oligomers (116847, 1.0 μmol/Kg dosegroup) were 116% relative to saline. This example demonstrates that the6-(S)—CH₃—BNA modification allows for the design of antisense oligomerswhich maintain the potency conferred by the 4′-CH₂—O-2′ BNA with adramatic improvement in the ALT levels over the 4′-CH₂—O-2′ BNA modifiedcompounds.

Example 49 6-(R or S)—CH₃, 6-(R or S)—CH₂—OCH₃, 4′-CH₂—O-2′ BNA 2-10-2Gapped Oligomers Targeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with modified 6-(R or S)—CH₃ (396568 and 396024respectively), 6-(R or S)—CH₂—OCH₃ (396007 and 396008 respectively),4′-CH₂—O-2′ BNA 2-10-2 gapped oligomers targeted to PTEN at a dose of2.5, 5, 10 and 20 μmol/kg (only 5 and 10 μmol/Kg data shown). The micewere sacrificed 66 hrs following administration. Liver tissues werehomogenized.

dose SEQ ID NO./ Composition (μmol/ ISIS NO. (5′ to 3′) kg) ALT 6-Subsaline 41.3 10/396024 U S C SATGGCTGCAGC S U S 10 250.5 CH₃ 10/396024 US C SATGGCTGCAGC S U S 5 72.0 CH₃ 10/396568 U R C RATGGCTGCAGC R U R 10234.3 CH₃ 10/396568 U R C RATGGCTGCAGC R U R 5 62.0 CH₃ 10/396008 U S CSATGGCTGCAGC S U S 10 129.5 CH₂—OCH₃ 10/396008 U S C SATGGC103-118TG 549.0 CH₂—OCH₃ CAGC S U S 10/396007 U R C RATGGCTGCAGC R U R 10 49.0CH₂—OCH₃ 10/396007 U R C RATGGCTGCAGC R U R 5 36.3 CH₂—OCH₃ 11/392056 Tl Me C lATGGCTGCAG 10 925.0 n/a Me C l T l 11/392056 T l Me ClATGGCTGCAG 5 373.0 n/a Me C l T l

All internucleoside linkages are phosphorothioate, bolded nucleosidesare modified nucleosides, subscript R and S indicate the configurationat the 6 carbon atom for 6-CH₃—BNA (bolded only) and 6-CH₂—O—CH₃—BNA(bolded an underlined) nucleosides as indicated, subscript I indicates4′-CH₂—O-2′ nucleosides and ^(Me)C indicates a 5′-methyl cytosinenucleoside.

Example 50 2-14-2 Gapped Oligomers Targeted to PTEN: In Vivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with 6-CH₃—BNA modified oligomers targeted to PTEN at adose of 2 or 10 μmol/kg. The mice were sacrificed 72 hrs followingadministration. Liver tissues were homogenized and mRNA levels werequantitated using real-time PCR as described herein for comparison tountreated control levels (% UTC).

SEQ ID NO./ Composition ISIS NO. (5′ to 3′) modification 12/394420 Me Ce T eGCTAGCCTCTGG Bold 2′-O-MOE ATT e T e 13/400522 C R URGCTAGCCTCTGGAT Bold 6-(R)—CH₃ U R U R 13/400523 C S U SGCTAGCCTCTGGATBold 6-(S)—CH₃ U S U S 13/400524 C R U RGCTAGCCTCTGGATBold 6-(R)—CH₂—O—CH₃ U R U R 13/400525 C S U SGCTAGCCTCTGGATBold 6-(S)—CH₂—O—CH₃ U S U S

dose ISIS NO. (μmol/kg) % UTC Standard deviation saline 100%  12% 394420 2 79% 2% 394420 10 26% 11%  400522 2 18% 3% 400522 10  4% 0%400523 2 17% 2% 400523 10  4% 1% 400524 2 23% 7% 400524 10  4% 0% 4005252 21% 3% 400525 10 3% 0%

All internucleoside linkages are phosphorothioate, bolded nucleosidesare modified nucleosides, subscript R and S indicate the configurationat the 6 carbon atom for 6-CH₃—BNA and 6-CH₂—O—CH₃—BNA nucleosides asindicated, subscript e indicates 2′-O-MOE nucleosides and ^(Me)Cindicates a 5′-methyl cytosine nucleoside.

Example 51 5′-Vinyl and LNA 2-14-2 Gapped Oligomers Targeted to PTEN: InVivo Study

Six week old Balb/c mice (Jackson Laboratory, Bar Harbor, Me.) wereinjected once with one of the modified oligomers listed below targetedto PTEN at a dose of 1.9, 6, 19 or 60 mg/kg for the 18 mers (411027 and394425) or 3.2, 10, 32 or 100 mg/kg for the 14 mers (425452, 392063 and410129). The mice were sacrificed 64 hrs following administration. Livertissues were homogenized and mRNA levels were quantitated usingreal-time PCR as described herein for comparison to untreated controllevels (% UTC). Data for oligomers 425452 and 392063 were obtained inone assay. Data for oligomers 410129 and 411027 were obtained in anotherassay. The data for 394425 was obtained in a separate assay but has beenrepeated and has been consistent. The modified nucleosides in the wingsfor the LNA gapped oligomers are 5-methylated whereas the modifiednucleosides in the wings of other modified oligomers are not5-methylated.

PTEN % UTC SEQ ID NO/ (mg/kg dose) ISIS NO Sequence 3.2 10 32 100saline (not dosed, 100% UTC) 05/425452 C_(i)U_(i)TAGCACTGGCC_(i)U_(i) 9380 36 7 08/392063 ^(Me)C_(l)T_(l)TAGCACTGGC^(Me)C_(l)T_(l) 92 29 36 705/410129 C_(v)U_(v)TAGCACTGGCC_(v)U_(v) 100 75 31 7 1.9 60 19 6013/411027 C_(v)U_(v)GCTAGCCTCTGGATU_(v)U_(v) 89 61 24 7 12/394425^(Me)C_(l)T_(l)GCTAGCCTCTGGATT_(l)T_(l) 100 35  8 4

Wherein the annotated nucleosides are illustrated below:

All internucleoside linkages are phosphorothioate, superscript Mepreceding a C indicates that the cytosine is a 5-(S)-methyl cytosine andall nucleosides not otherwise annotated are β-D-2′-deoxyribonucleosides.

SEQ ID NO./ ED₅₀ ALT (IU/L) ISIS NO. Tm (mg/kg) 3.2 10 32 100 05/42545256.3° C. 20.8 26 28 23 22.5 08/392063 60.5° C. 7.0 9.5 12.5 9.75 1867005/410129 52.9° C. 18.5 35 33 30 27 13/411027 59.9° C. 7.4 26 40 27 3812/394425 61.6° C. 4.4 31 28 55 1445

The Tm for the three 14 mers (425452, 392063 and 410129) was determinedby melting against the RNA 14 mer (394098) complement and the Tm for thetwo 18 mers (392063 and 394425) was determined by melting against theRNA 20 mer (131566) which has a 14 base complementary region to the 18mers.

SEQ ID NO./ ISIS NO. RNA Sequence (5′ to 3′) 14/131566UCAAAUCCAGAGGCUAGCAG 15/394098 AGGCCAGUGCUAAG.

1. An oligomeric compound having the formula:G-[T-L]_(j)-[R-L]_(q)-R-[L-T]_(r)-E wherein: each T is a monomer ofFormula V:

wherein independently for each monomer having Formula V: Bx is aheterocyclic base moiety; one of Z₁ and Z₂ is H, C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl or substituted C₂-C₆ alkynyl and the other one of Z₁ and Z₂ isC₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl; one of Q₁ and Q₂ isH, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substitutedC₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, thiol orsubstituted thiol and the other one of Q₁ and Q₂ is C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl, substituted C₂-C₆ alkynyl, thiol or substituted thiol; or Q₁and Q₂ together are methylene (═CH₂); each R is aβ-D-2′-deoxyribonucleoside; each L is an internucleoside linking group;G and E are each, independently, H, a hydroxyl protecting group, alinked conjugate group or a 5′ or 3′-terminal group; wherein eachsubstituted group is mono or poly substituted with substituent groupsindependently selected from halogen, OJ₁, SJ₁, NJ₁J₂, N₃, COOJ₁, CN,O—C(═O)NJ₁J₂, N(H)C(═NH)NJ₁J₂, N(H)C(═O)N(H)J₂ or N(H)C(═S)N(H)J₂; eachJ₁ and J₂ is, independently, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ aminoalkyl or a protecting group; q is from 7 to about15; j is 0 or from 1 to about 5; r is 0 or from 1 to about 5; and thesum of j and r is at least
 1. 2. The oligomeric compound of claim 1wherein for each monomer having Formula V, Z₁ or Z₂ is H and the otherof Z₁ and Z₂ is C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl,substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl.3. The oligomeric compound of claim 2 wherein the other of Z₁ and Z₂ isCH₂F, CHF₂ or CF₃.
 4. The oligomeric compound of claim 2 wherein theother of Z₁ and Z₂ is C₁-C₆ alkyl or substituted C₁-C₆ alkyl.
 5. Theoligomeric compound of claim 2 wherein the other of Z₁ and Z₂ is CH₃. 6.The oligomeric compound of claim 1 wherein for each monomer havingFormula V, Q₁ and Q₂ are each, independently, H, C₁-C₆ alkyl orsubstituted C₁-C₆ alkyl wherein at least one of Q₁ and Q₂ is other thanH.
 7. The oligomeric compound of claim 1 wherein for each monomer havingFormula V, one of Q₁ and Q₂ is H and the other of Q₁ and Q₂ is C₁-C₆alkyl or substituted C₁-C₆ alkyl.
 8. The oligomeric compound of claim 7wherein the other of Q₁ and Q₂ is CH₃.
 9. The oligomeric compound ofclaim 1 wherein for each monomer having Formula V, one of Q₁ and Q₂ is Hand the other of Q₁ and Q₂ is CH₂F, CHF₂ or CF₃.
 10. The oligomericcompound of claim 1 wherein for each monomer having Formula V, Q₁ and Q₂are each CH₃.
 11. The oligomeric compound of claim 1 wherein for eachmonomer having Formula V, Q₁ and Q₂ together are methylene (═CH₂). 12.The oligomeric compound of claim 1 wherein for each monomer havingFormula V, one of Q₁ and Q₂ is H, the other of Q₁ and Q₂ is CH₃, one ofZ₁ or Z₂ is H and the other of Z₁ and Z₂ is CH₃.
 13. The oligomericcompound of claim 1 wherein for each monomer having Formula V, Bx isuracil, thymine, cytosine, 5-methylcytosine, 2,6-diaminopurine, adenineor guanine.
 14. The oligomeric compound of claim 1 wherein eachinternucleoside linking group is, independently, a phosphodiester orphosphorothioate.
 15. The oligomeric compound of claim 1 wherein eachinternucleoside linking group is a phosphorothioate.
 16. The oligomericcompound of claim 1 wherein for each monomer having Formula V, Z₂ and Q₂are each H.
 17. The oligomeric compound of claim 16 wherein Z₁ and Q₁are each CH₃ for each monomer having Formula V.
 18. The oligomericcompound of claim 1 wherein Z₂ and Q₁ are each H for each monomer havingFormula V.
 19. The oligomeric compound of claim 18 wherein Z₁ and Q₂ areeach CH₃ for each monomer having Formula V.
 20. The oligomeric compoundof claim 1 wherein Z₁ and Q₂ are each H for each monomer having FormulaV.
 21. The oligomeric compound of claim 20 wherein Z₂ and Q₁ are eachCH₃ for each monomer having Formula V.
 22. The oligomeric compound ofclaim 1 wherein Z₁ and Q₁ are each H for each monomer having Formula V.23. The oligomeric compound of claim 22 wherein Z₂ and Q₂ are each CH₃for each monomer having Formula V.
 24. The oligomeric compound of claim1 comprising from about 8 to about 20 monomeric subunits.
 25. Theoligomeric compound of claim 1 comprising from about 10 to about 16monomeric subunits.
 26. The oligomeric compound of claim 1 comprisingfrom about 10 to about 14 monomeric subunits.